[
    {
        "question": "Which of the following four compounds is most likely to test positive in the Ames mutagenesis assay (Colonies >=2 fold) based on the public experimental data?",
        "options": [
            "a. CC(=O)Nc1cc2c(cc1O)-c1ccccc1C2",
            "b. O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1",
            "c. O=C1c2ccccc2C(=O)N1CCl",
            "d. ClCCC(Br)CBr"
        ],
        "answer": "c",
        "answer_smiles": "O=C1c2ccccc2C(=O)N1CCl",
        "domain": "Ames",
        "id": 1
    },
    {
        "question": "Which of the following four compounds is most likely to test positive in the Ames mutagenesis assay (Colonies >=2 fold) based on the public experimental data?",
        "options": [
            "a. O=C(/C=C/c1ccccc1[N+](=O)[O-])c1ccccc1",
            "b. CCOC(=O)CNC(=O)CBr",
            "c. C[C@H](I)[C@@H]1OC[C@@H](CO)O1",
            "d. C1CNCCN1"
        ],
        "answer": "c",
        "answer_smiles": "C[C@H](I)[C@@H]1OC[C@@H](CO)O1",
        "domain": "Ames",
        "id": 3
    },
    {
        "question": "Which of the following four compounds is most likely to test positive in the Ames mutagenesis assay (Colonies >=2 fold) based on the public experimental data?",
        "options": [
            "a. CC(/C=C(\\C#N)c1ccc(Cl)c(Cl)c1)C(c1ccccc1)C(C#N)c1ccc(Cl)c(Cl)c1",
            "b. O=C1CCCCCN1",
            "c. CC(C)(C)c1cc(-c2ccccc2)ccc1[N+](=O)[O-]",
            "d. CCCCOCCOC(=O)COc1ccc(Cl)cc1Cl"
        ],
        "answer": "a",
        "answer_smiles": "CC(/C=C(\\C#N)c1ccc(Cl)c(Cl)c1)C(c1ccccc1)C(C#N)c1ccc(Cl)c(Cl)c1",
        "domain": "Ames",
        "id": 9
    },
    {
        "question": "Which of the following four compounds is most likely to cross the blood-brain barrier (BBB) (lgBBB>=-1) based on the public experimental data?",
        "options": [
            "a. COC1OC2OC3(CN4CCCCC4)C(O)CC(C2C)C13",
            "b. N=c1nc(N2CCCCC2)cc(N)n1O",
            "c. CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OC1COC2OCCC12)S(=O)(=O)c1ccc(N)cc1",
            "d. Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1"
        ],
        "answer": "a",
        "answer_smiles": "COC1OC2OC3(CN4CCCCC4)C(O)CC(C2C)C13",
        "domain": "BBB",
        "id": 14
    },
    {
        "question": "Which of the following four compounds is most likely to cross the blood-brain barrier (BBB) (lgBBB>=-1) based on the public experimental data?",
        "options": [
            "a. OCC(O)C1OC2OC(C(Cl)(Cl)Cl)OC2C1O",
            "b. c1ccc(NC2=NCCN2)cc1",
            "c. O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CSC2C(NC(=O)C(O)c3ccccc3)C(=O)N12",
            "d. CC(C)CC1NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(Cc2ccccc2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(Cc2ccccc2)NC1=O"
        ],
        "answer": "a",
        "answer_smiles": "OCC(O)C1OC2OC(C(Cl)(Cl)Cl)OC2C1O",
        "domain": "BBB",
        "id": 19
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the breast cancer resistance protein (BCRP) transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COCCc1ccc(OCC(O)CNC(C)C)cc1",
            "b. COc1c(OC)c2c(=O)cc(C)oc2c2c(OC)cc(O)cc12",
            "c. CC(=O)N1CCN(c2cc(-c3ccccc3)nc3cc(-c4ccccc4)nn23)CC1",
            "d. COc1ccc(OCC(=O)Nc2ccccc2C(=O)N2CCOCC2)cc1"
        ],
        "answer": "c",
        "answer_smiles": "CC(=O)N1CCN(c2cc(-c3ccccc3)nc3cc(-c4ccccc4)nn23)CC1",
        "domain": "BCRPi",
        "id": 24
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the breast cancer resistance protein (BCRP) transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. N#CC(=Cc1ccc(N2CCCCC2)o1)C(=O)Nc1ccc(Cl)cc1",
            "b. COc1ccc(S(=O)(=O)c2cnc3ccc(OC)cc3c2N2CCC3(CC2)OCCO3)cc1",
            "c. COc1ccc(C(=O)C=Cc2ccccc2)c(O)c1",
            "d. O=C(Nc1ccc(CCN2CCc3ccccc3C2)cc1)c1ccc([N+](=O)[O-])cc1"
        ],
        "answer": "d",
        "answer_smiles": "O=C(Nc1ccc(CCN2CCc3ccccc3C2)cc1)c1ccc([N+](=O)[O-])cc1",
        "domain": "BCRPi",
        "id": 25
    },
    {
        "question": "Which of the following four compounds is most likely to act as a BSEP (bile salt export pump) inhibitor (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(C)(CO)C(O)C(=O)NCCC(=O)O",
            "b. Cn1ccnc1S",
            "c. Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O",
            "d. Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1"
        ],
        "answer": "d",
        "answer_smiles": "Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1",
        "domain": "BSEPi",
        "id": 37
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a dog hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1ncc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)c(C2CCCC2)n1",
            "b. CC(C(=O)Nc1ccc(F)cc1)C12CC(NC(=O)c3ccc(F)c(F)c3)(C1)C2",
            "c. COCc1ccc(-c2ccc3ncc(C(N)=O)c(NC(C)C4CCOCC4)c3c2)cn1",
            "d. COc1cc(Nc2nn(C3COCCC3C#N)cc2C(N)=O)ccc1Cl"
        ],
        "answer": "b",
        "answer_smiles": "CC(C(=O)Nc1ccc(F)cc1)C12CC(NC(=O)c3ccc(F)c(F)c3)(C1)C2",
        "domain": "CLhepa_dog",
        "id": 42
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a human hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC(Oc1cc2cc(F)cc(F)c2nc1N)c1[nH]c(=O)ccc1-n1cccn1",
            "b. COc1ccc2c(c1)OC(c1ccc(OC)c(OC)c1)CC2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1",
            "c. Cc1cc(-c2ccc(C(=O)C3CCCCC3C(=O)Nc3cn(C)nc3C(N)=O)cc2)n[nH]1",
            "d. OCC1OC(Sc2cncc(Br)c2)C(O)C(n2cc(-c3cc(F)c(F)c(F)c3)nn2)C1O"
        ],
        "answer": "b",
        "answer_smiles": "COc1ccc2c(c1)OC(c1ccc(OC)c(OC)c1)CC2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1",
        "domain": "CLhepa_human",
        "id": 53
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a human hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COc1ccc(-c2cc3c(C(=O)O)c[nH]c3cc2Cl)cn1",
            "b. C=C(CC(=O)OC1(c2cc(Cl)ccc2Cl)CCC1)C(=O)OCC(=O)O",
            "c. CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CCC(O)CC(O)CC(=O)O",
            "d. CCOc1ccc2ccc(=O)oc2c1"
        ],
        "answer": "c",
        "answer_smiles": "CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CCC(O)CC(O)CC(=O)O",
        "domain": "CLhepa_human",
        "id": 55
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a human hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1ccc2c(c1)OCC(C)(CS(C)(=O)=O)N2C(=O)c1ccc2c(c1)NC(=O)CO2",
            "b. COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1",
            "c. CCS(=O)(=O)c1ccc(C(NC(C)=O)C(=O)Nc2cc(-c3cc(C#N)cc(F)c3OC)cs2)cc1",
            "d. COc1cc(-c2cn(C)c(=O)c(C)c2C)cc(OC)c1CN1CCC(N2CCN(c3ccc(NC4CCC(=O)NC4=O)cc3F)CC2)C(F)(F)C1"
        ],
        "answer": "a",
        "answer_smiles": "Cc1ccc2c(c1)OCC(C)(CS(C)(=O)=O)N2C(=O)c1ccc2c(c1)NC(=O)CO2",
        "domain": "CLhepa_human",
        "id": 57
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=C(Nc1ccn(-c2ccnc(F)c2)n1)C1(c2ccccc2F)CC1",
            "b. CCC(=O)c1csc(C(=O)c2c[nH]c3c(F)cccc23)n1",
            "c. C=C(CC(=O)OC1(c2ccc(Br)cn2)CCC1)C(=O)O",
            "d. CC(C)CC=C(CC(=O)NC(C)c1ccc(C(F)(F)F)cc1)C(=O)O"
        ],
        "answer": "d",
        "answer_smiles": "CC(C)CC=C(CC(=O)NC(C)c1ccc(C(F)(F)F)cc1)C(=O)O",
        "domain": "CLhepa_mice",
        "id": 61
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(CCc4ccccc4)cc3)c2)cc(OC)c1OC",
            "b. Oc1n[nH]c2cc(Cl)ccc12",
            "c. Nc1nnc(-c2csc(C(=O)c3c[nH]c4ccccc34)n2)s1",
            "d. OCC1OC(Sc2cncc(Br)c2)C(O)C(n2cc(-c3cc(F)c(F)c(F)c3)nn2)C1O"
        ],
        "answer": "a",
        "answer_smiles": "COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(CCc4ccccc4)cc3)c2)cc(OC)c1OC",
        "domain": "CLhepa_mice",
        "id": 66
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a monkey hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(-c2cn(C)c(=O)c3[nH]ccc23)c1",
            "b. CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCC(NCC(F)(F)F)CC1",
            "c. CC1OC(=O)C2(N)CC(F)(F)C(C)C(C=Cc3ccc(-c4ccccc4C#N)cn3)C12",
            "d. CNS(=O)(=O)Nc1cccc(Cc2c(CN(C)C)c3cc(F)c(OC(=O)N(C)C)cc3oc2=O)c1F"
        ],
        "answer": "a",
        "answer_smiles": "CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(-c2cn(C)c(=O)c3[nH]ccc23)c1",
        "domain": "CLhepa_monkey",
        "id": 72
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a monkey hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COc1cc(-c2ccc3c(n2)C(C)N(c2cnn(CC(F)(F)F)c2)C3=O)cnc1OC",
            "b. CC(O)c1nc2cnc3[nH]ccc3c2n1C1CCCOC1",
            "c. COC(=O)Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)c3cc(CN4CCN(S(C)(=O)=O)CC4)cn3n2)cn1",
            "d. Clc1ccc2c(c1)CC1(Cc3nnc(C4CCC(Oc5ccccn5)CC4)n3-2)OCCO1"
        ],
        "answer": "d",
        "answer_smiles": "Clc1ccc2c(c1)CC1(Cc3nnc(C4CCC(Oc5ccccn5)CC4)n3-2)OCCO1",
        "domain": "CLhepa_monkey",
        "id": 76
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. C=C1CC(=CC)C(=O)OC2CCN3CC=C(COC(=O)C1(O)CO)C23",
            "b. COc1cnc(C(=O)Nc2ccc(F)c(C3(C)CCC(F)(CF)C(N)=N3)c2)cn1",
            "c. O=c1[nH]c(=O)n(Cc2ccccc2)cc1-c1cc(F)cc(F)c1",
            "d. CCCSc1nc(N2CCC(CC(=O)O)CC2)ccc1C(=O)NC1CCCCC1"
        ],
        "answer": "c",
        "answer_smiles": "O=c1[nH]c(=O)n(Cc2ccccc2)cc1-c1cc(F)cc(F)c1",
        "domain": "CLhepa_rat",
        "id": 81
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CN(C)C(=O)CNCCc1cccc(OCCCC(F)(F)F)c1",
            "b. Cc1nc(-c2cccc(C(F)(F)F)c2)sc1C(=O)NC1CN(S(=O)(=O)c2ccccc2)CC1C(=O)NC1CCCNC1",
            "c. CC(F)(F)C1CN(c2ccc3nccc(C(=O)NCC(=O)N4CSCC4C#N)c3c2)C1",
            "d. O=C(O)c1cccc(C(=O)O)c1"
        ],
        "answer": "a",
        "answer_smiles": "CN(C)C(=O)CNCCc1cccc(OCCCC(F)(F)F)c1",
        "domain": "CLhepa_rat",
        "id": 83
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cn1cc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cn1",
            "b. CNc1nc(Nc2cnn(C3COC3)c2C)ncc1C(F)(F)F",
            "c. CC1Cc2c(ccc3[nH]ncc23)C(C)(c2c(F)cc(C=CC(=O)O)cc2F)N1CC(C)(F)F",
            "d. CN(C)C(=O)CN1CCC(c2cc3c(-c4ccc(=O)n(C5CCOCC5)c4)ccnc3[nH]2)CC1"
        ],
        "answer": "c",
        "answer_smiles": "CC1Cc2c(ccc3[nH]ncc23)C(C)(c2c(F)cc(C=CC(=O)O)cc2F)N1CC(C)(F)F",
        "domain": "CLhepa_rat",
        "id": 86
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat hepatocyte assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1",
            "b. N#CC1CSCN1C(=O)CNC(=O)c1ccnc2ccc(-c3cnn(C4CC4)c3)cc12",
            "c. C=CC(=O)N1CCC(n2cc(-c3ccncc3)c(-c3cccc(NC(=O)c4ncc(C5CC5)o4)c3)n2)C1",
            "d. COCC1CN(c2ccc3nccc(C(=O)NCC(=O)N4CSCC4C#N)c3c2)CCO1"
        ],
        "answer": "c",
        "answer_smiles": "C=CC(=O)N1CCC(n2cc(-c3ccncc3)c(-c3cccc(NC(=O)c4ncc(C5CC5)o4)c3)n2)C1",
        "domain": "CLhepa_rat",
        "id": 90
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in dogs, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=c1ccc2ccc(F)c3c2n1CC3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1",
            "b. O=C(NCc1ccc(Cl)cc1)c1cn(N2CCOCC2)c2ccc(CN3CCOCC3)cc2c1=O",
            "c. N#Cc1cccc(S(=O)(=O)c2cnc3cc(F)ccc3c2-c2ccc(Cl)cc2)c1",
            "d. CC1Cc2c(ccc3[nH]ncc23)C(c2c(F)cc(C=CC(=O)O)cc2F)N1CC(C)(F)F"
        ],
        "answer": "a",
        "answer_smiles": "O=c1ccc2ccc(F)c3c2n1CC3CN1CCC(NCc2cc3c(nn2)OCCO3)CC1",
        "domain": "CLinvivo_dog",
        "id": 91
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in dogs, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1cc(F)ccc1C1CC(N2CCN3C(=O)CCC3C2)CCN1C(=O)N(C)C(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1",
            "b. COc1ccccc1CCC1CCc2cc(C3CCC(N)(CO)C3)ccc2C1",
            "c. CSC1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1",
            "d. CC(=NO)c1nc(C(O)C(O)C(O)CO)c[nH]1"
        ],
        "answer": "a",
        "answer_smiles": "Cc1cc(F)ccc1C1CC(N2CCN3C(=O)CCC3C2)CCN1C(=O)N(C)C(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1",
        "domain": "CLinvivo_dog",
        "id": 92
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in dogs, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC1(C)OCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O",
            "b. COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl",
            "c. CCc1nc(OC)c(NC(=O)N2CCN(c3cc(C)cc(C)c3)CC2)cc1C(=O)NC(C)C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1",
            "d. C#CC(CC(=O)O)NC(=O)CCC(=O)Nc1ccc(C(=N)N)cc1"
        ],
        "answer": "b",
        "answer_smiles": "COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl",
        "domain": "CLinvivo_dog",
        "id": 93
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in dogs, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=C(c1ccc(F)cc1)N1CCc2nc(COc3ccccc3)oc2C1",
            "b. CCn1c(C(C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21",
            "c. CCCN1CC(c2ccc(N)nc2)OCC1C",
            "d. CC1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl"
        ],
        "answer": "a",
        "answer_smiles": "O=C(c1ccc(F)cc1)N1CCc2nc(COc3ccccc3)oc2C1",
        "domain": "CLinvivo_dog",
        "id": 100
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in humans, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC1CNC(C2CC2)C(=O)N(C)C(C)C(=O)NC(Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1",
            "b. Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1",
            "c. CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O",
            "d. CC1C(=O)OC2C(O)C34C5CC(C(C)(C)C)C36C(OC(=O)C6O)OC4(C(=O)O5)C12O"
        ],
        "answer": "c",
        "answer_smiles": "CC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1ccccc1C3=O",
        "domain": "CLinvivo_human",
        "id": 107
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in humans, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=NN(CCCl)C(=O)NCCCl",
            "b. CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2C1OC(COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)C(O)C1O",
            "c. COCC1OC(OC2OCC3OC4(OCC(OC(=O)c5c(C)cc(O)cc5O)C5OCOC54)OC3C2O)C(OC)C(O)C1OC1OC(C)C(OC)C(OC2OC(C)C3OC4(CC(O)C(OC5CC(OC6CC(C)([N+](=O)[O-])C(OC)C(C)O6)C(OC(=O)c6c(C)c(Cl)c(O)c(Cl)c6OC)C(C)O5)C(C)O4)OC3(C)C2O)C1O",
            "d. Cn1nnc(-c2ccc(-c3ccc(N4CC(CO)OC4=O)cc3F)cn2)n1"
        ],
        "answer": "b",
        "answer_smiles": "CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2C1OC(COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)C(O)C1O",
        "domain": "CLinvivo_human",
        "id": 110
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in mice, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COCCOC1CCC(Nc2cc(=O)n(C)c3c(C)cc(-c4cncs4)cc23)CC1",
            "b. Nc1n[nH]c(N2CCC(NS(=O)(=O)Cc3ccc(Br)cc3)CC2)n1",
            "c. Fc1cccc(C2Cc3[nH]nc(-c4nnn[nH]4)c3C2)c1",
            "d. CCCCCCCCCCNC1(C)CC(OC2C(Oc3c4cc5cc3Oc3ccc(cc3Cl)C(O)C3NC(=O)C(NC(=O)C5NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)c5ccc(c(Cl)c5)O4)c4ccc(O)c(c4)-c4c(O)cc(O)cc4C(C(=O)NCCCNC(=O)C(O)C(O)C(OC4OC(CO)C(O)C(O)C4O)C(O)CO)NC3=O)OC(CO)C(O)C2O)OC(C)C1O"
        ],
        "answer": "c",
        "answer_smiles": "Fc1cccc(C2Cc3[nH]nc(-c4nnn[nH]4)c3C2)c1",
        "domain": "CLinvivo_mice",
        "id": 111
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in mice, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. C#Cc1cnc2nc(O)n(C(CC)CC)c2n1",
            "b. c1cncc(OCC2CNCCN2c2nc3ncccc3o2)c1",
            "c. CC1C(NC(=O)C(=NOCc2cc(=O)c(O)cn2O)c2cccs2)C(=O)N1S(=O)(=O)O",
            "d. CCCCCCCCCCCCCCCCNCCCNCCCNCCCCNCCCN"
        ],
        "answer": "b",
        "answer_smiles": "c1cncc(OCC2CNCCN2c2nc3ncccc3o2)c1",
        "domain": "CLinvivo_mice",
        "id": 114
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in mice, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CCc1nnc(-c2ccc(-c3ccccc3)nc2)n1-c1cccc(C#N)c1C",
            "b. Nc1nc(C(=NOC2(C(=O)O)CC2)C(=O)NC2C(=O)N(S(=O)(=O)O)C2CN2CCOC2=O)cs1",
            "c. CCON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C=CC[n+]3ccc(-c4cc(C(=O)NC#N)[nH]n4)cc3)CSC12)c1csc(N)n1",
            "d. CC(Nc1cc(=O)n(C(C)C)c(=O)[nH]1)c1ccccc1"
        ],
        "answer": "a",
        "answer_smiles": "CCc1nnc(-c2ccc(-c3ccccc3)nc2)n1-c1cccc(C#N)c1C",
        "domain": "CLinvivo_mice",
        "id": 116
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in monkeys, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1",
            "b. CCN=C(NCC)NCCCCC(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(=NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(N)=O",
            "c. CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)C(CC(=O)O)CC3",
            "d. Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1"
        ],
        "answer": "d",
        "answer_smiles": "Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1",
        "domain": "CLinvivo_monkey",
        "id": 121
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in monkeys, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1",
            "b. Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1",
            "c. CN1Cc2cc(N3CCOCC3)ccc2C(c2ccc3sccc3c2)C1",
            "d. Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1"
        ],
        "answer": "c",
        "answer_smiles": "CN1Cc2cc(N3CCOCC3)ccc2C(c2ccc3sccc3c2)C1",
        "domain": "CLinvivo_monkey",
        "id": 122
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in monkeys, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COc1ccc(C(CC(=O)O)N2CCN(CCCc3ccc4c(n3)NCCC4)C2=O)cn1",
            "b. CC(C)C1NC(=O)C(Cc2cccs2)NC(=O)C(Cc2ccc(Cl)cc2)NC(=O)CCCSCC(C(=O)N2CCCC2C(=O)NCCCCNC(=N)N)NC(=O)C(CC(N)=O)NC1=O",
            "c. CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C",
            "d. CC(c1ccc(F)cc1CCCC(=O)O)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1"
        ],
        "answer": "c",
        "answer_smiles": "CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(Cc1cnc[nH]1)C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C",
        "domain": "CLinvivo_monkey",
        "id": 126
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in monkeys, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12",
            "b. CCC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1",
            "c. COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O",
            "d. O=C(CCS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2Cc3cnc(CO)n3C2=O)CC1"
        ],
        "answer": "b",
        "answer_smiles": "CCC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1",
        "domain": "CLinvivo_monkey",
        "id": 128
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in rats, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1ccccc1Nc1nc2ccc(CC(=O)N3CC(F)CC3COC3CCC(C(=O)O)CC3)cc2o1",
            "b. CC1CCC(C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1",
            "c. O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1",
            "d. O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12"
        ],
        "answer": "b",
        "answer_smiles": "CC1CCC(C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1",
        "domain": "CLinvivo_rat",
        "id": 132
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in rats, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC(C)(N)C(NC(=O)c1ccc(C#CC#CC2CC2CO)cc1)C(=O)NO",
            "b. CCOC(=O)C1=C(c2ccc(-n3c(C)nc4cnccc43)cc2)NC(C)=C(C(=O)Nc2ccccn2)C1c1ccccc1Cl",
            "c. CCCS(=O)(=O)Nc1ccc(F)c(C(=O)Nc2cnc3[nH]nc(OC)c3c2)c1F",
            "d. COC(=O)N1CC(F)CC1c1nc(C(=O)NCc2ccc(F)c(Cl)c2)c(O)c(=O)n1C"
        ],
        "answer": "d",
        "answer_smiles": "COC(=O)N1CC(F)CC1c1nc(C(=O)NCc2ccc(F)c(Cl)c2)c(O)c(=O)n1C",
        "domain": "CLinvivo_rat",
        "id": 133
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in rats, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Oc1ccc2nc(CN3CCC(Cc4ccccc4F)CC3)[nH]c2c1",
            "b. O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)c(F)cc1F)N1CCN(c2ccccn2)CC1",
            "c. CN1CCN(c2ccc(N3CC(CO)OC3=O)cc2F)C=N1",
            "d. Cc1ncn(-c2ccc(Nc3nccc(-c4cccc(N5CCOCC5)c4)n3)cc2)n1"
        ],
        "answer": "b",
        "answer_smiles": "O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)c(F)cc1F)N1CCN(c2ccccn2)CC1",
        "domain": "CLinvivo_rat",
        "id": 137
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in vivo in rats, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. O=C(O)C1CCC(c2cc3cccnc3c(-c3cccc(OC(F)(F)F)c3)n2)CC1",
            "b. O=P1(NCCCl)OCCCN1CCCl",
            "c. CC1NC(c2cc(C#N)ccn2)=NC1(c1ccc(F)cc1)c1ccc(F)nc1",
            "d. N#CC1CC(F)(F)CN1C(=O)CNC(=O)c1ccnc2ccccc12"
        ],
        "answer": "c",
        "answer_smiles": "CC1NC(c2cc(C#N)ccn2)=NC1(c1ccc(F)cc1)c1ccc(F)nc1",
        "domain": "CLinvivo_rat",
        "id": 139
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the cytochrome P450 1A2 (CYP1A2) enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)[C@@]1(Cc2ccccc2)[C@@H]2c3cc(C(=O)N(C)C)n(Cc4cc(F)c(F)c(F)c4)c3C[C@H]2CN1C(=O)c1ccccc1",
            "b. CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1",
            "c. O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",
            "d. CC(C)C[C@@H](CC(=O)N[C@@H](CCCN)CC(=O)N[C@@H]1CCNC[C@H]1C(=O)N[C@H](CC(=O)N[C@@H](CCC(=O)O)CC(=O)O)Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CNCC[C@H]1N"
        ],
        "answer": "b",
        "answer_smiles": "CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1",
        "domain": "CYP1A2I",
        "id": 143
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2C19 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1cccc(N2CCN(CC(=O)Nc3ccc(-n4cnnn4)cc3)CC2)c1C",
            "b. C[C@@H](C(=O)Nc1ccc2ccccc2c1)[C@@H]1C[C@@]1(C)[C@@H](NC(=O)OCc1ccccc1)c1ccccc1",
            "c. O=C(Nc1cccc(F)c1)N1CCC2(CC1)CCN(C(=O)c1ccncc1)CC2",
            "d. O=C1CNCCCN2CCN(CCCNCC(=O)Nc3ccc(cc3)S(=O)(=O)c3ccc(cc3)NC(=O)CNCCCN3CCN(CCCNCC(=O)Nc4ccc(cc4)S(=O)(=O)c4ccc(cc4)N1)CC3)CC2"
        ],
        "answer": "b",
        "answer_smiles": "C[C@@H](C(=O)Nc1ccc2ccccc2c1)[C@@H]1C[C@@]1(C)[C@@H](NC(=O)OCc1ccccc1)c1ccccc1",
        "domain": "CYP2C19I",
        "id": 151
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2C19 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCN1C(=O)[C@H]2[C@H]3[C@H](O)[C@H](O)C/C(=N/OC[C@@H]4O[C@H](c5ccccc5)C=C[C@@H]4Oc4ccc(OC)cc4)[C@@H]3CC[C@@H]2C1=O",
            "b. COCC(=O)N1CCC2(CC1)CN(Cc1ccc(C#N)cc1)C2",
            "c. O=C(c1cnccn1)N1CCC2(CC1)CCN(c1ncccn1)CC2",
            "d. COc1ccc(C(=O)N2CCC3(CCCN(Cc4ccncc4)C3)CC2)cc1"
        ],
        "answer": "a",
        "answer_smiles": "CCN1C(=O)[C@H]2[C@H]3[C@H](O)[C@H](O)C/C(=N/OC[C@@H]4O[C@H](c5ccccc5)C=C[C@@H]4Oc4ccc(OC)cc4)[C@@H]3CC[C@@H]2C1=O",
        "domain": "CYP2C19I",
        "id": 155
    },
    {
        "question": "Which of the following four compounds is most likely to act as an inhibitor of the CYP450 2C9 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COc1ccc(C(C(=O)NC2CCCCC2)N(C(=O)c2sc(C)nc2C)c2ccc(C(C)=O)cc2)cc1",
            "b. COc1cccc(Cn2c(=O)c(C)nc3cnc(N4CCOCC4)nc32)c1",
            "c. O=C(O)Cc1cccnc1",
            "d. C/C(CCN1CCCCc2nc(C)c(C)cc21)=N\\O[C@@H](C)c1cn([C@@H]2COC[C@@H]2O)nn1"
        ],
        "answer": "b",
        "answer_smiles": "COc1cccc(Cn2c(=O)c(C)nc3cnc(N4CCOCC4)nc32)c1",
        "domain": "CYP2C9I",
        "id": 161
    },
    {
        "question": "Which of the following four compounds is most likely to act as an inhibitor of the CYP450 2C9 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Nc1ccc(S(=O)(=O)NCc2nccs2)cc1",
            "b. COc1ccc(CNc2ncnc3ccc(-c4ccccc4C#N)cc23)c(OC)c1",
            "c. CN1CCN(CC(=O)N2c3ccccc3Sc3cc4ccccc4cc32)CC1",
            "d. CC(=O)N1CCC[C@@]2(CCN(C(=O)Nc3cccc(C#N)c3)C2)C1"
        ],
        "answer": "b",
        "answer_smiles": "COc1ccc(CNc2ncnc3ccc(-c4ccccc4C#N)cc23)c(OC)c1",
        "domain": "CYP2C9I",
        "id": 164
    },
    {
        "question": "Which of the following four compounds is most likely to act as an inhibitor of the CYP450 2C9 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)[C@@H](N)CCCN=C(N)N[N+](=O)[O-]",
            "b. Cc1cccc(N/C(S)=N/C2CC3CCCC(C2)N3Cc2cccs2)c1",
            "c. O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CCCN(c3ccccn3)C2)CC1",
            "d. CNC(=O)COC(=O)c1cc2c(C)nn(-c3ccc(F)cc3)c2s1"
        ],
        "answer": "d",
        "answer_smiles": "CNC(=O)COC(=O)c1cc2c(C)nn(-c3ccc(F)cc3)c2s1",
        "domain": "CYP2C9I",
        "id": 169
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for CYP450 2C9 (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",
            "b. Cc1cccc(C)c1NC(=O)[C@H](C)N",
            "c. C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C",
            "d. CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21"
        ],
        "answer": "c",
        "answer_smiles": "C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C",
        "domain": "CYP2C9S",
        "id": 174
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for CYP450 2C9 (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C1C(CC[S@@H+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1",
            "b. CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1",
            "c. COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1",
            "d. CCCCc1ncc(/C=C(/Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1"
        ],
        "answer": "a",
        "answer_smiles": "O=C1C(CC[S@@H+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1",
        "domain": "CYP2C9S",
        "id": 175
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for CYP450 2C9 (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1",
            "b. CC(C)(Oc1ccc([C@@H]2CC2(Cl)Cl)cc1)C(=O)O",
            "c. COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O",
            "d. C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O"
        ],
        "answer": "d",
        "answer_smiles": "C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O",
        "domain": "CYP2C9S",
        "id": 176
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for CYP450 2C9 (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1",
            "b. COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@H]1c1cccc([N+](=O)[O-])c1",
            "c. CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1",
            "d. CN(C)CCC=C1c2ccccc2C=Cc2ccccc21"
        ],
        "answer": "a",
        "answer_smiles": "OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1",
        "domain": "CYP2C9S",
        "id": 178
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2D6 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CN1[C@@H]2CC(OC(=O)[C@@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@H]12",
            "b. COCC(=O)N1CCC2(CCCN(Cc3ccccc3)C2)CC1",
            "c. c1nc(NCCc2cnc[nH]2)c2[nH]cnc2n1",
            "d. CC(C)(C)NS(=O)(=O)c1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1"
        ],
        "answer": "d",
        "answer_smiles": "CC(C)(C)NS(=O)(=O)c1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1",
        "domain": "CYP2D6I",
        "id": 181
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2D6 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)C1C(c2ccccc2)C2C(=O)c3c(OC)cc(OC)cc3O[C@@]12c1ccc(OC)cc1",
            "b. Fc1ccc(CSc2ncnc3sc4c(c23)CCCC4)cc1",
            "c. COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1",
            "d. c1cncc(-c2nccc(NCc3cccs3)n2)c1"
        ],
        "answer": "d",
        "answer_smiles": "c1cncc(-c2nccc(NCc3cccs3)n2)c1",
        "domain": "CYP2D6I",
        "id": 184
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2D6 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. C[C@H](N)Cc1cnc[nH]1",
            "b. Cc1ncn(-c2ccccc2O)c1C",
            "c. C=C1CC[C@@H](O)C/C1=C/C=C1\\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CCCC(C)C",
            "d. CCC(c1nnnn1CC1CCCO1)N(CCN1CCOCC1)Cc1cc2cc(C)ccc2nc1O"
        ],
        "answer": "b",
        "answer_smiles": "Cc1ncn(-c2ccccc2O)c1C",
        "domain": "CYP2D6I",
        "id": 185
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the CYP450 2D6 enzyme (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COc1ccc(N2CCN(C(=O)CSc3nnc4c5cc(C)ccc5n(C)c4n3)CC2)cc1",
            "b. CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",
            "c. COc1ccc(N2C(=O)CC(SC(=N)N/N=C(\\C)c3cccs3)C2=O)cc1",
            "d. CC(=O)NCc1c(Cl)cccc1-n1cccc1"
        ],
        "answer": "b",
        "answer_smiles": "CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",
        "domain": "CYP2D6I",
        "id": 190
    },
    {
        "question": "Which of the following four compounds is most likely to be a substrate of the CYP450 2D6 enzyme (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O",
            "b. O=NN(CCCl)C(=O)NC1CCCCC1",
            "c. Cn1c(=O)c2[nH]cnc2n(C)c1=O",
            "d. Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2"
        ],
        "answer": "c",
        "answer_smiles": "Cn1c(=O)c2[nH]cnc2n(C)c1=O",
        "domain": "CYP2D6S",
        "id": 194
    },
    {
        "question": "Which of the following four compounds is most likely to act as an inhibitor of the enzyme CYP450 3A4 (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=[N+]([O-])c1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2F)c([N+](=O)[O-])c1",
            "b. Nc1ncnc2[nH]c(N3CCN(CCO)CC3)nc12",
            "c. c1ccc([C@H]2CNCc3ccccc32)cc1",
            "d. O=C(O)c1cccc(N2CCCC2=O)c1"
        ],
        "answer": "d",
        "answer_smiles": "O=C(O)c1cccc(N2CCCC2=O)c1",
        "domain": "CYP3A4I",
        "id": 208
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high Caco2 cell permeability (Papp>=10x10-6cm/s) based on the public experimental data?",
        "options": [
            "a. Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1",
            "b. COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)/C=C/c3cc(OC)c(OC)c(OC)c3)cc1)CC2",
            "c. COc1ccc(N(C)c2cnc(SCc3c(F)cccc3F)n2-c2ccc(F)cc2)cc1OC",
            "d. COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(C(C)(C)CO)cc2)CC3)cc1"
        ],
        "answer": "a",
        "answer_smiles": "Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1",
        "domain": "Caco2",
        "id": 212
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high Caco2 cell permeability (Papp>=10x10-6cm/s) based on the public experimental data?",
        "options": [
            "a. CC(=O)N1CCN(c2cccc(-c3cc(-c4ncco4)c4c(N)ncnn34)c2)C(=O)C1(C)C",
            "b. O=C1C[C@@H](c2ccc(C[C@H](Nc3nc4ccccc4s3)c3nc4ccccc4[nH]3)cc2F)S(=O)(=O)N1",
            "c. CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccn1)c1ccccc1",
            "d. CS(=O)(=O)NCc1cccc(-c2cc(=O)n(CC3CN4CCC3CC4)c3ccccc23)c1"
        ],
        "answer": "a",
        "answer_smiles": "CC(=O)N1CCN(c2cccc(-c3cc(-c4ncco4)c4c(N)ncnn34)c2)C(=O)C1(C)C",
        "domain": "Caco2",
        "id": 214
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high Caco2 cell permeability (Papp>=10x10-6cm/s) based on the public experimental data?",
        "options": [
            "a. CCCC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3Cl)CC2)nc1C",
            "b. O=C(N[C@@H](Cc1ccc(F)c(Br)c1)C(=O)O)c1ccc(Br)cc1NS(=O)(=O)c1cccc2nsnc12",
            "c. CC(=O)Nc1ccc(Nc2nc3c(-c4ccc(C(=O)NCCOc5ccccc5)cc4)cccn3n2)cc1",
            "d. C[C@@H]1O[C@@H](/C=C/c2ccccc2)OC[C@H]1NC(=O)Cc1ccccc1"
        ],
        "answer": "c",
        "answer_smiles": "CC(=O)Nc1ccc(Nc2nc3c(-c4ccc(C(=O)NCCOc5ccccc5)cc4)cccn3n2)cc1",
        "domain": "Caco2",
        "id": 220
    },
    {
        "question": "Which of the following four compounds is the most likely to be carcinogenic based on the public experimental data?",
        "options": [
            "a. CCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1",
            "b. CCCCCC[C@H]1C(=O)O[C@H](C)C(NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C",
            "c. c1cncc(C2=NCCC2)c1",
            "d. CN1CC[C@@]2(C)c3cc(O)ccc3N(C)[C@H]12"
        ],
        "answer": "a",
        "answer_smiles": "CCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1",
        "domain": "Carc",
        "id": 221
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity toward HEK293 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C)C(OC(=O)CCCC/C(=N/NC(=O)CCCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2c[nH]c3ccccc23)[C@@H](C)O)C(=O)O)C1=O)c1ccccc1)c1ccccc1)OC)N(C)C(=O)C(C)NC(=O)C(C(C)C)N(C)C",
            "b. CCC[C@@H](CCO)Nc1nc(N)nc2ccc(F)cc12",
            "c. CNCCCN1c2ccccc2CCc2ccccc21",
            "d. CCOC(=O)C12CC1(Cc1ccccc1)c1cc(Cl)ccc1NC2=O"
        ],
        "answer": "a",
        "answer_smiles": "CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C)C(OC(=O)CCCC/C(=N/NC(=O)CCCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2c[nH]c3ccccc23)[C@@H](C)O)C(=O)O)C1=O)c1ccccc1)c1ccccc1)OC)N(C)C(=O)C(C)NC(=O)C(C(C)C)N(C)C",
        "domain": "CytotoxHEK293",
        "id": 234
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity toward HEK293 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OCCOCCOC(=O)CCCC=CCCC=CCCCC(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C",
            "b. COc1ccc(OC)c(N(CC(=O)Nc2ccc(Cl)cc2)S(=O)(=O)c2ccc(C)cc2)c1",
            "c. O=C(NCCN1CCCC1)c1ccc2oc(C(=O)c3cc(O)c(O)c(O)c3)cc2c1",
            "d. O=C1Nc2ccc(Br)cc2C12N(c1ccccc1)N=C(c1ccccc1)N2c1ccc(Cl)cc1"
        ],
        "answer": "a",
        "answer_smiles": "CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OCCOCCOC(=O)CCCC=CCCC=CCCCC(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C",
        "domain": "CytotoxHEK293",
        "id": 235
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity toward HEK293 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCCCNc1nc(N)nc2c1CN(C(=O)c1cc(C)on1)CC2",
            "b. CCCCNc1nc(N)nc(C)c1Oc1ccccc1",
            "c. Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1",
            "d. CCc1ncnc(NC(CC)c2ccc([N+](=O)[O-])cc2)c1Cl"
        ],
        "answer": "c",
        "answer_smiles": "Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1",
        "domain": "CytotoxHEK293",
        "id": 239
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity against HepG2 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C1OCCc2c(CO)cccc21",
            "b. CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1n1cc([N+](=O)[O-])c2ccc(NCc3ccccc3)cc21",
            "c. C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)nc(N)[nH]c21",
            "d. COC(=O)[C@@H]1C(C=NCCN=CC2=Cc3cc4c(cc3[C@@H](c3cc(OC)c(OC)c(OC)c3)[C@@H]2C(=O)OC)OCO4)=Cc2cc3c(cc2[C@H]1c1cc(OC)c(OC)c(OC)c1)OCO3"
        ],
        "answer": "c",
        "answer_smiles": "C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)nc(N)[nH]c21",
        "domain": "CytotoxHepG2",
        "id": 243
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity against HepG2 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COc1ccc(C(=O)Nc2c[nH]c3ccc(-c4csc5c(F)cccc45)nc3c2=O)cc1OC",
            "b. Fc1cnc(N2CCOCC2)nc1N1CCc2ccccc21",
            "c. COc1ccc2nc3cc(Cl)ccc3c(NCCCCNC(C)=O)c2c1",
            "d. COc1cc(C(=O)NCC(O)(c2ccc(OC)c(-c3ccc(F)c(Br)c3)n2)C(F)(F)F)ccc1OCC(N)=O"
        ],
        "answer": "c",
        "answer_smiles": "COc1ccc2nc3cc(Cl)ccc3c(NCCCCNC(C)=O)c2c1",
        "domain": "CytotoxHepG2",
        "id": 246
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity against HepG2 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1nnc(NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2C)o1",
            "b. CCCNc1ccc2c([N+](=O)[O-])cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)c2c1",
            "c. CCCCCCCCCCCCCCCCCCCCOCCCOP(=O)(O)COC1(Cn2cnc3cnc(N)nc32)CC1",
            "d. Cc1ccc(NC(=O)c2ccc([N+](=O)[O-])o2)c(C)c1"
        ],
        "answer": "c",
        "answer_smiles": "CCCCCCCCCCCCCCCCCCCCOCCCOP(=O)(O)COC1(Cn2cnc3cnc(N)nc32)CC1",
        "domain": "CytotoxHepG2",
        "id": 250
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxic effects on Huh7 liver cancer cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3[C@@H]4CC[C@@H](C4)[C@H]3N(Cc3ccc(F)cc3)C1=O)N2",
            "b. CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3(CC3)CN(Cc3ccc(F)cc3)C1=O)N2",
            "c. Cc1ccn(C(=O)NCCNC(=O)Nc2ccc(Cc3ccc(NC(=O)NCCNC(=O)n4ccc(C)n4)cc3)cc2)n1",
            "d. COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C(=O)OCc2ccccc2)c2ccccc2)Oc2cccc3ccccc23)[C@@H](O)[C@@]1(C)O"
        ],
        "answer": "b",
        "answer_smiles": "CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3(CC3)CN(Cc3ccc(F)cc3)C1=O)N2",
        "domain": "CytotoxHuh7",
        "id": 252
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxic effects on Huh7 liver cancer cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1ccc(-c2cc(-c3ccccc3)c(C#N)c(SCC(O)C[S+]([O-])Cc3ccccc3)n2)cc1",
            "b. Nc1ncnc2c1c(-c1ccc3ccccc3c1)cn2[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F",
            "c. CSCCN1CCc2ccc3[nH]cc(-c4cccc(Cl)c4)c3c2C1",
            "d. CCCN(C)c1nn(CCC(C)C)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O"
        ],
        "answer": "d",
        "answer_smiles": "CCCN(C)c1nn(CCC(C)C)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O",
        "domain": "CytotoxHuh7",
        "id": 255
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity against MRC5 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Nc1ncnc2c1c(-c1c[nH]cn1)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
            "b. O=C(CN1CCCCC1)Nc1cc(COC(=O)NCCCN2CCNCC2)cc(Nc2ccnc3cc(Cl)ccc23)c1",
            "c. Cl[Au](Cl)Cl.Cl[Au](Cl)Cl.c1cc(-c2ccncc2)ccn1",
            "d. CC(C)(C)OC(=O)[C@H](CC1CCCCC1)NCCCN[C@@H](CC1CCCCC1)C(=O)OC(C)(C)C.Cl.Cl.I[Pt]I"
        ],
        "answer": "a",
        "answer_smiles": "Nc1ncnc2c1c(-c1c[nH]cn1)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
        "domain": "CytotoxMRC5",
        "id": 268
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit cytotoxicity against MRC5 cells (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. C=C1C(=O)[C@]2(C)C(=O)O[C@@]34C[C@H](C)C(C(=O)O)=C[C@@H]3CCC[C@H](C)C[C@@H](C)[C@H]1O[C@H]24",
            "b. CCCCCCCCCCCCCCCC(=O)O[Pt](Cl)(Cl)OC(=O)CCCC(=O)OCn1cc(F)c(=O)[nH]c1=O.N.N",
            "c. Nc1ncnc2c1c(-c1ccccc1)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",
            "d. CN1O[C@H](n2cc3ccoc3nc2=O)C[C@@H]1CO"
        ],
        "answer": "a",
        "answer_smiles": "C=C1C(=O)[C@]2(C)C(=O)O[C@@]34C[C@H](C)C(C(=O)O)=C[C@@H]3CCC[C@H](C)C[C@@H](C)[C@H]1O[C@H]24",
        "domain": "CytotoxMRC5",
        "id": 270
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit Vero cytotoxicity (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCC(C)C(=O)O[C@@H]1[C@H]2[C@@H](OC(C)=O)[C@@H](C)C[C@]2(O)C(=O)[C@@](C)(OC(C)=O)[C@@H]2[C@@H]3[C@H](C[C@@H](OC(C)=O)[C@@]12COC(C)=O)C3(C)C",
            "b. CCCCCCCCCCC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O",
            "c. Cc1cn([C@@H]2C[C@H]3CCCN3O2)c(=O)[nH]c1=O",
            "d. O=C(CN1CCN(c2ccccc2)CC1)Nc1ccc(-c2nc3cc(C(F)(F)F)ccc3n2C23CC4CC(CC(C4)C2)C3)cc1"
        ],
        "answer": "b",
        "answer_smiles": "CCCCCCCCCCC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O",
        "domain": "CytotoxVero",
        "id": 271
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit Vero cytotoxicity (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1ccn2c(NC3CCCC3)c(-c3ccccn3)nc2c1",
            "b. CN(C)c1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](NC(=O)[C@@H](N)CSCc2ccccc2)[C@H]1O",
            "c. CC(C(/C=N/NC(=S)NCc1ccccc1)=N\\NC(=S)NCc1ccccc1)N1C(=O)c2ccccc2C1=O",
            "d. CC(=O)OC[C@H]1O[C@@H](n2cc(C(F)CBr)c(=O)[nH]c2=O)C[C@@H]1OC(C)=O"
        ],
        "answer": "b",
        "answer_smiles": "CN(C)c1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](NC(=O)[C@@H](N)CSCc2ccccc2)[C@H]1O",
        "domain": "CytotoxVero",
        "id": 272
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit Vero cytotoxicity (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1cc(C)n(Cc2ccc(NC(=O)c3nn(C)cc3[N+](=O)[O-])cc2)n1",
            "b. CC(C)c1ccc(C=NNC(=O)/C=C/c2ccc(C(C)(C)C)cc2)cc1",
            "c. Cc1cc2c(cc1C)[n+]([O-])c(/C=N/NC(=O)c1ccncc1)c(C)[n+]2[O-]",
            "d. CC(/C=N/NC(=O)c1[nH]nc2c1CCC2)=C\\c1ccccc1"
        ],
        "answer": "d",
        "answer_smiles": "CC(/C=N/NC(=O)c1[nH]nc2c1CCC2)=C\\c1ccccc1",
        "domain": "CytotoxVero",
        "id": 274
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit Vero cytotoxicity (CC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COc1ccc(NC(=O)CCCN2C(=O)/C(=C\\c3ccco3)SC2=S)cc1",
            "b. CO[C@H]1C2=CO[C@@]3(O)[C@H](O)CO[C@H]4O[C@@H]([C@@H]2[C@]43O)[C@]2(C)CC[C@@]3(C)CCC(C(C)C)=C3[C@H]2[C@H]1O",
            "c. CC(=O)C1=C(O)C(=O)N(c2cc(C(C)(C)C)on2)C1c1ccc(C(C)C)cc1",
            "d. CC1(C)[C@H](O)C[C@H](O)[C@]2(C)[C@H]3CC[C@@]4(C)[C@H](c5ccoc5)OC(=O)[C@H]5O[C@]54[C@]3(C)C(=O)C[C@@H]12"
        ],
        "answer": "b",
        "answer_smiles": "CO[C@H]1C2=CO[C@@]3(O)[C@H](O)CO[C@H]4O[C@@H]([C@@H]2[C@]43O)[C@]2(C)CC[C@@]3(C)CCC(C(C)C)=C3[C@H]2[C@H]1O",
        "domain": "CytotoxVero",
        "id": 280
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit drug-induced liver toxicity based on the public experimental data?",
        "options": [
            "a. COc1ccc2c3c1OC1C(O)CCC4C(C2)N(C)CCC341",
            "b. O=C1CCC(=O)N1c1ccc(Cl)c(Cl)c1",
            "c. CN=C(NC)NCc1ccccc1",
            "d. COc1ccc2[nH]cc(CCNC(C)=O)c2c1"
        ],
        "answer": "d",
        "answer_smiles": "COc1ccc2[nH]cc(CCNC(C)=O)c2c1",
        "domain": "DILT",
        "id": 281
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit drug-induced liver toxicity based on the public experimental data?",
        "options": [
            "a. COc1ccc2c3c1OC1C(O)CCC4C(C2)N(C)CCC341",
            "b. CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2",
            "c. CC(=O)C(=O)O",
            "d. CCN1C(=O)NC(c2ccccc2)C1=O"
        ],
        "answer": "b",
        "answer_smiles": "CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2",
        "domain": "DILT",
        "id": 282
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a human microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. COc1ccc(S(=O)(=O)N2C(=O)C(c3cc(CN4CCN(C)CC4)ccc3OC)(N3CCCC3C(=O)N(C)C)c3cc(Cl)ccc32)cc1",
            "b. CC(C)(C)CC1NC(C(=O)Nc2ccn(CC(C)(C)O)n2)C(c2cccc(Cl)c2F)C1(C#N)c1ccc(Cl)cc1F",
            "c. CCc1ccc(-c2ccc(C(=O)N(C)C3CCN(C(=O)N4CCC(NC5CCOCC5)C4)C3)cc2)cc1",
            "d. Cc1nnc(C2CCN(c3ccccn3)CC2)n1-c1ccc(C#N)cc1"
        ],
        "answer": "a",
        "answer_smiles": "COc1ccc(S(=O)(=O)N2C(=O)C(c3cc(CN4CCN(C)CC4)ccc3OC)(N3CCCC3C(=O)N(C)C)c3cc(Cl)ccc32)cc1",
        "domain": "HMS",
        "id": 302
    },
    {
        "question": "Which of the following four compounds is most likely to have high human oral bioavailability (%F>=80%) based on the public experimental data?",
        "options": [
            "a. Oc1ccc2c(c1)C13CCCCC1(O)C(C2)N(CC1CCC1)CC3",
            "b. Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1",
            "c. CCCN1CC(CSC)CC2c3cccc4[nH]cc(c34)CC21",
            "d. Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1"
        ],
        "answer": "b",
        "answer_smiles": "Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1",
        "domain": "HOB",
        "id": 314
    },
    {
        "question": "Which of the following four compounds is most likely to have high human oral bioavailability (%F>=80%) based on the public experimental data?",
        "options": [
            "a. Clc1ccc2nsnc2c1NC1=NCCN1",
            "b. COc1ccc2c3c1OC1C(O)C=CC4C(C2)N(C)CCC341",
            "c. Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1",
            "d. CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I"
        ],
        "answer": "c",
        "answer_smiles": "Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1",
        "domain": "HOB",
        "id": 316
    },
    {
        "question": "Which of the following four compounds is most likely to have high human oral bioavailability (%F>=80%) based on the public experimental data?",
        "options": [
            "a. NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12",
            "b. O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21",
            "c. CC(=O)OC1(C(C)=O)CCC2C3CC(C)C4=CC(=O)CCC4(C)C3CCC21C",
            "d. CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21"
        ],
        "answer": "a",
        "answer_smiles": "NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12",
        "domain": "HOB",
        "id": 318
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in mice based on the public experimental data?",
        "options": [
            "a. O=C1CCCN2C(=N1)Oc1cc(Cl)ccc12",
            "b. O=C1C(O)OCCN1CC(O)Cn1c([N+](=O)[O-])cnc1C(F)(F)F",
            "c. CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1C",
            "d. Brc1cncnc1-c1cccs1"
        ],
        "answer": "d",
        "answer_smiles": "Brc1cncnc1-c1cccs1",
        "domain": "LD50mice",
        "id": 321
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in mice based on the public experimental data?",
        "options": [
            "a. COc1cc2c(cc1OC)Nc1ncnc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c1N=C2",
            "b. CCc1ccc(CCOc2ccc(CC3SC(=O)N(CC(=O)c4ccc(-c5ccccc5)cc4)C3=O)cc2)nc1",
            "c. CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23",
            "d. Cc1c(C)c2c(c(C)c1N)CC(C)(CN1CCN(c3cccc(-n4ccnc4)c3)CC1)O2"
        ],
        "answer": "c",
        "answer_smiles": "CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23",
        "domain": "LD50mice",
        "id": 325
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in mice based on the public experimental data?",
        "options": [
            "a. CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(OC(=O)C(F)CCN(C)C)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C",
            "b. CN(C)C(=O)NC1CCC(CCN2CCN(c3cccc4ccsc34)CC2)CC1",
            "c. CC1CCc2c(N3CCC(O)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23",
            "d. CC(=CC(=O)c1ccccc1)NNC(=O)c1ccncc1"
        ],
        "answer": "a",
        "answer_smiles": "CC(=O)OC12COC1CC(O)C1(C)C(=O)C(O)C3=C(C)C(OC(=O)C(OC(=O)C(F)CCN(C)C)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C",
        "domain": "LD50mice",
        "id": 328
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in mice based on the public experimental data?",
        "options": [
            "a. CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21",
            "b. CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N",
            "c. COc1cc(C=CC(=O)OC2CCC3(C)C(=CCC4(O)C3CC(OC(=O)C=C(C)C(C)C)C3(C)C(O)(C(C)=O)CCC43O)C2)cc(OC)c1OC",
            "d. O=c1oc2ccccc2c(O)c1C1=NN(c2ccccc2)C(c2cccnc2)C1"
        ],
        "answer": "a",
        "answer_smiles": "CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21",
        "domain": "LD50mice",
        "id": 329
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. O=C(O)CCCC(=O)Nc1ccc(O)c(C(=O)O)c1",
            "b. O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O",
            "c. Cc1c(C(N)=O)sc2c1c(=O)n(Cc1ccccc1)c1n[nH]c(=O)n21",
            "d. COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(=N)c1ccc(F)c(F)c1)CC2"
        ],
        "answer": "c",
        "answer_smiles": "Cc1c(C(N)=O)sc2c1c(=O)n(Cc1ccccc1)c1n[nH]c(=O)n21",
        "domain": "LD50rat",
        "id": 331
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. COc1cc(CC(=O)Nc2ccncc2)cc(OC)c1OC",
            "b. CC(=O)c1nn(-c2ccc(Cl)cc2)c2nc3nc4onc(-c5ccccc5)c4c(-c4ccc(Cl)cc4)c3c(=O)n12",
            "c. CN(C)c1ccc(C=CC(=O)c2c(O)ccc3c(-c4ccccc4)cc(=O)oc23)cc1",
            "d. O=C(NN1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(NC(=O)c1cc(O)nc(O)c1)C3=O)c1cc(O)nc(O)c1"
        ],
        "answer": "c",
        "answer_smiles": "CN(C)c1ccc(C=CC(=O)c2c(O)ccc3c(-c4ccccc4)cc(=O)oc23)cc1",
        "domain": "LD50rat",
        "id": 332
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC",
            "b. COc1cc(CC(=O)Nc2ccncc2)cc(OC)c1OC",
            "c. CC(C=Cc1ccccc1)=NOC(C)C(N)=O",
            "d. CCN(CC)CCOC(=O)c1ccccc1OC(C)=O"
        ],
        "answer": "a",
        "answer_smiles": "COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC",
        "domain": "LD50rat",
        "id": 334
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. O=C(CNc1ccc(Cl)cc1)NN=Cc1cccc(Br)c1",
            "b. Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1",
            "c. NC(=O)c1cc[n+](CCC[n+]2ccc(C=NO)cc2)cc1",
            "d. NC(=O)c1ccc[n+](CC=CC[n+]2ccc(C=NO)cc2)c1"
        ],
        "answer": "d",
        "answer_smiles": "NC(=O)c1ccc[n+](CC=CC[n+]2ccc(C=NO)cc2)c1",
        "domain": "LD50rat",
        "id": 337
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. O=C1c2c(Br)c(Br)c(Br)c(Br)c2C(=O)N1Cc1ccccn1",
            "b. N=c1c2c3c(sc2nc(S)n1C(=O)c1ccccc1)CCCC3",
            "c. COc1cccc(N2CCN(C(=O)c3c(-c4cccc(F)c4)noc3C)CC2)c1",
            "d. NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O"
        ],
        "answer": "b",
        "answer_smiles": "N=c1c2c3c(sc2nc(S)n1C(=O)c1ccccc1)CCCC3",
        "domain": "LD50rat",
        "id": 338
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. CC1CN(Cc2cccc3c2ccn3-c2ccccc2-c2nnn[nH]2)CC(C)O1",
            "b. CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc([S+](C)[O-])cc1",
            "c. CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",
            "d. O=C(NCCO)c1ccc(Cl)cn1"
        ],
        "answer": "b",
        "answer_smiles": "CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc([S+](C)[O-])cc1",
        "domain": "LD50rat",
        "id": 339
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit an LD50 ≥500 mg/kg in rats based on the public experimental data?",
        "options": [
            "a. COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(=N)c1cccc(C)c1)CC2",
            "b. CC1CCCCN1C1=C([O-])C(O)C(C)(N2CCCCC2C)C1",
            "c. CN1CCC(c2c(O)cc(O)c3c(=O)cc(C=Cc4c(Cl)cccc4Cl)oc23)C(O)C1",
            "d. O=C(CCc1ccc(O)c(O)c1)CC(CCc1ccc(O)c(O)c1)OC1OCC(O)C(O)C1O"
        ],
        "answer": "b",
        "answer_smiles": "CC1CCCCN1C1=C([O-])C(O)C(C)(N2CCCCC2C)C1",
        "domain": "LD50rat",
        "id": 340
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the MATE1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1",
            "b. CN(C)CCOC(c1ccccc1)c1ccccc1",
            "c. CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12",
            "d. CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]cc(c56)CC4N(C)C3)(C(C)C)C(=O)N12"
        ],
        "answer": "d",
        "answer_smiles": "CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]cc(c56)CC4N(C)C3)(C(C)C)C(=O)N12",
        "domain": "MATE1i",
        "id": 347
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the MATE1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1",
            "b. CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1",
            "c. COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC",
            "d. Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl"
        ],
        "answer": "c",
        "answer_smiles": "COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC",
        "domain": "MATE1i",
        "id": 348
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the MATE1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Nc1nc2ccc(OC(F)(F)F)cc2s1",
            "b. C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C",
            "c. CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1",
            "d. CC(=O)Nc1ccc(O)cc1"
        ],
        "answer": "b",
        "answer_smiles": "C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C",
        "domain": "MATE1i",
        "id": 349
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the MATE1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CN(C)C1C(=O)C(C(N)=O)=C(O)C2(O)C(O)=C3C(=O)c4c(O)cccc4C(C)(O)C3CC12",
            "b. CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O",
            "c. CN(C)CCCN1c2ccccc2CCc2ccccc21",
            "d. CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1"
        ],
        "answer": "d",
        "answer_smiles": "CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1",
        "domain": "MATE1i",
        "id": 350
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl",
            "b. CC(C)OC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1(C)c1ccc(F)cc1",
            "c. Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(C2CC2)cc1",
            "d. CC(=O)Nc1cc(NC(=O)c2c(Cl)cccc2Cl)ccn1"
        ],
        "answer": "a",
        "answer_smiles": "Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl",
        "domain": "MMS",
        "id": 352
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC(C)n1ncnc1-c1cn2c(n1)-c1ccc(-c3cnn(CCO)c3)cc1OCC2",
            "b. CCC(F)(F)c1nc2nc(C)cc(Nc3ccc(S(F)(F)(F)(F)F)cc3)n2n1",
            "c. CCn1ccc2cc(NC(=O)Nc3ccc(OC(CCN(C)C)c4ccccc4)cc3)ccc21",
            "d. CC(NC1CCN(c2ccc(-c3nn[nH]n3)cc2)C1)c1cccc2ccccc12"
        ],
        "answer": "d",
        "answer_smiles": "CC(NC1CCN(c2ccc(-c3nn[nH]n3)cc2)C1)c1cccc2ccccc12",
        "domain": "MMS",
        "id": 355
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1",
            "b. CN(Cc1nnc(-c2ccco2)o1)Cc1c(F)cccc1Cl",
            "c. CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1",
            "d. CCNC(=O)CC1N=C(c2ccc(Cl)cc2)c2ccccc2-c2c(C)noc21"
        ],
        "answer": "a",
        "answer_smiles": "Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1",
        "domain": "MMS",
        "id": 356
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a mice microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC(O)(CN1CCc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1",
            "b. COc1cc(C(=O)Nc2cc(OC(F)(F)F)ccc2-n2cncn2)ccc1OC1CC1",
            "c. CCCc1nc(Nc2cc(NCCN)nnc2C(N)=O)ccc1OC",
            "d. CCC(C)(C)C(=O)NCc1ccccc1"
        ],
        "answer": "a",
        "answer_smiles": "CC(O)(CN1CCc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1",
        "domain": "MMS",
        "id": 357
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor androgen receptor ligand-binding domain (AR LBD) (<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1cc(CCC(=O)OCCOCCOCCOC(=O)CCc2cc(C)c(O)c(C(C)(C)C)c2)cc(C(C)(C)C)c1O",
            "b. CCCCCOC(=O)c1ccccc1C(=O)OCCCCC",
            "c. CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(O)cc13",
            "d. CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O"
        ],
        "answer": "d",
        "answer_smiles": "CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O",
        "domain": "NR-AR-LBD",
        "id": 362
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor androgen receptor ligand-binding domain (AR LBD) (<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1cccc(Oc2ccccc2)c1",
            "b. [N-]=[N+]=C1C=Cc2c(cccc2S(=O)(=O)O)C1=O",
            "c. c1cc2ccc3ccc4ccc5cccc6c(c1)c2c3c4c56",
            "d. C[C@H](C(=O)O)c1cccc(Oc2ccccc2)c1"
        ],
        "answer": "c",
        "answer_smiles": "c1cc2ccc3ccc4ccc5cccc6c(c1)c2c3c4c56",
        "domain": "NR-AR-LBD",
        "id": 365
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor androgen receptor ligand-binding domain (AR LBD) (<=10uM) based on the public experimental data?",
        "options": [
            "a. FC(F)(F)c1ccccc1",
            "b. O=C(O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F",
            "c. O=C(CCl)C(Cl)Cl",
            "d. CCCCCCCC/C=C\\CCCCCCCC(=O)OCCOC(=O)CCCCCCC/C=C\\CCCCCCCC"
        ],
        "answer": "c",
        "answer_smiles": "O=C(CCl)C(Cl)Cl",
        "domain": "NR-AR-LBD",
        "id": 368
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the androgen receptor (AR) nuclear receptor (<=10uM) based on the public experimental data?",
        "options": [
            "a. Nc1ccc(Cl)cc1N",
            "b. Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1",
            "c. CC1(C)[C@H](C(=O)O[C@H](C#N)c2cccc(Oc3ccccc3)c2)[C@@H]1C=C(Br)Br",
            "d. CC(=O)Nc1nnc(S(N)(=O)=O)s1"
        ],
        "answer": "a",
        "answer_smiles": "Nc1ccc(Cl)cc1N",
        "domain": "NR-AR",
        "id": 376
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the androgen receptor (AR) nuclear receptor (<=10uM) based on the public experimental data?",
        "options": [
            "a. CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1",
            "b. c1csc(-c2ccc(-c3cccs3)s2)c1",
            "c. COc1cc(-c2nc(NC(=O)c3cc4cc(C)cc(C)c4n3CC(=O)O)sc2CCC2CCCCC2)c(OC)cc1Cl",
            "d. O=P(O)(O)OC(CO)CO"
        ],
        "answer": "b",
        "answer_smiles": "c1csc(-c2ccc(-c3cccs3)s2)c1",
        "domain": "NR-AR",
        "id": 379
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the androgen receptor (AR) nuclear receptor (<=10uM) based on the public experimental data?",
        "options": [
            "a. OCCCBr",
            "b. CO[Si](CCCOCC1CO1)(OC)OC",
            "c. CC(=O)C=Cc1ccc2c(c1)OCO2",
            "d. NNc1ccc(C(=O)O)cc1"
        ],
        "answer": "d",
        "answer_smiles": "NNc1ccc(C(=O)O)cc1",
        "domain": "NR-AR",
        "id": 380
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor AhR (aryl hydrocarbon receptor) (<=10uM) based on the public experimental data?",
        "options": [
            "a. CCCCCCCC(=O)Oc1c(Br)cc(C#N)cc1Br",
            "b. C=Cc1ccccc1C=C",
            "c. O=C(CS)Nc1ccccc1",
            "d. CCCNC(C)C(=O)Nc1ccccc1C"
        ],
        "answer": "c",
        "answer_smiles": "O=C(CS)Nc1ccccc1",
        "domain": "NR-AhR",
        "id": 385
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor AhR (aryl hydrocarbon receptor) (<=10uM) based on the public experimental data?",
        "options": [
            "a. CCN(CC)c1nc(C)cc(OP(=S)(OC)OC)n1",
            "b. CCN(Cc1c(F)cccc1Cl)c1c([N+](=O)[O-])cc(C(F)(F)F)cc1[N+](=O)[O-]",
            "c. O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12",
            "d. CC(C)COC(=O)c1ccccc1C(=O)OCC(C)C"
        ],
        "answer": "a",
        "answer_smiles": "CCN(CC)c1nc(C)cc(OP(=S)(OC)OC)n1",
        "domain": "NR-AhR",
        "id": 388
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor Aromatase (<=10uM) based on the public experimental data?",
        "options": [
            "a. CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1",
            "b. CCC(=O)OCCOc1ccccc1",
            "c. CCCCCCCCCCCC(=O)O",
            "d. O=C(Cc1ccccc1)c1ccccc1"
        ],
        "answer": "a",
        "answer_smiles": "CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1",
        "domain": "NR-Aromatase",
        "id": 391
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor Aromatase (<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C(O)c1ccccc1C(=O)O",
            "b. CCCCCCCCCCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC",
            "c. CC1(C)[C@@H]2CC[C@@]1(C)[C@H](OC(=O)CSC#N)C2",
            "d. O=c1cccccc1O"
        ],
        "answer": "d",
        "answer_smiles": "O=c1cccccc1O",
        "domain": "NR-Aromatase",
        "id": 396
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor estrogen receptor ligand-binding domain (ER LBD) (<=10uM) based on the public experimental data?",
        "options": [
            "a. C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SC3Cn4cnc[n+]4C3)[C@H](C)[C@H]12",
            "b. CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",
            "c. Clc1cc(Cl)c(Cl)nc1Cl",
            "d. C1CCCCCCCCCCC1"
        ],
        "answer": "b",
        "answer_smiles": "CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",
        "domain": "NR-ER-LBD",
        "id": 406
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear receptor estrogen receptor ligand-binding domain (ER LBD) (<=10uM) based on the public experimental data?",
        "options": [
            "a. C=C(Cl)Cl",
            "b. N#CSCSC#N",
            "c. CC(=O)OCC=Cc1ccccc1",
            "d. CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1"
        ],
        "answer": "b",
        "answer_smiles": "N#CSCSC#N",
        "domain": "NR-ER-LBD",
        "id": 410
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear estrogen receptor (ER) (<=10uM) based on its molecular structure based on the public experimental data?",
        "options": [
            "a. CCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2",
            "b. CC(C)(C#N)/N=N/C(C)(C)C#N",
            "c. CC(C)COP(=O)(OCC(C)C)OCC(C)C",
            "d. N#CCCl"
        ],
        "answer": "d",
        "answer_smiles": "N#CCCl",
        "domain": "NR-ER",
        "id": 411
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear estrogen receptor (ER) (<=10uM) based on its molecular structure based on the public experimental data?",
        "options": [
            "a. O=C(CS)Nc1ccccc1",
            "b. Cc1c(-c2cccnc2)c2ccccc2n1CCCCC(=O)O",
            "c. NC(=O)NC1NC(=O)NC1=O",
            "d. N[Pt](N)(Cl)Cl"
        ],
        "answer": "a",
        "answer_smiles": "O=C(CS)Nc1ccccc1",
        "domain": "NR-ER",
        "id": 412
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear estrogen receptor (ER) (<=10uM) based on its molecular structure based on the public experimental data?",
        "options": [
            "a. CCCCOC(O)CC",
            "b. C=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)OCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O",
            "c. CC[N+](C)(C)c1cccc(O)c1",
            "d. Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O"
        ],
        "answer": "d",
        "answer_smiles": "Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O",
        "domain": "NR-ER",
        "id": 414
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the nuclear estrogen receptor (ER) (<=10uM) based on its molecular structure based on the public experimental data?",
        "options": [
            "a. CC[C@@]1(c2ccccc2)NC(=O)N(C)C1=O",
            "b. Cc1ccc(N=Nc2c(O)ccc(N=Nc3ccc(S(=O)(=O)O)cc3)c2O)c(C)c1",
            "c. CCCCCCCCC=O",
            "d. CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN"
        ],
        "answer": "d",
        "answer_smiles": "CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN",
        "domain": "NR-ER",
        "id": 419
    },
    {
        "question": "Which of the following four compounds is most likely to interact with an agonist or ligand for the nuclear receptor PPAR纬 (<=10uM) based on the public experimental data?",
        "options": [
            "a. C=CC(=C)CCC=C(C)C",
            "b. CCN(CC)CCSC(=O)C(c1ccccc1)c1ccccc1",
            "c. CCCCCCC/C=C/C=O",
            "d. CN(C)C(=O)Nc1ccc(Oc2ccc(Cl)cc2)cc1"
        ],
        "answer": "b",
        "answer_smiles": "CCN(CC)CCSC(=O)C(c1ccccc1)c1ccccc1",
        "domain": "NR-PPARg",
        "id": 424
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O",
            "b. COc1cc([C@@H]2c3cc4c(cc3[C@@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O",
            "c. COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1",
            "d. CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O"
        ],
        "answer": "c",
        "answer_smiles": "COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1",
        "domain": "OATP1b1i",
        "id": 431
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC[C@H]1/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]2[C@H](C)[C@H](CC1)O[C@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)[C@H]2C",
            "b. CC(=O)O[C@]1(C)CC[C@@]23C[C@H]1C(C)(C)[C@@H]2CC[C@H]3C",
            "c. COC(=O)[C@@H]1OC(=O)[C@H]2O[C@]23[C@@]2(C)[C@H](CC[C@@]13C)[C@@]1(C)CCC(=O)C(C)(C)[C@@H]1C[C@H]2OC(C)=O",
            "d. COc1c(CC(=O)c2cc3c(cc2O)OC(C)(C)C(O)C3)ccc2c1C=CC(C)(C)O2"
        ],
        "answer": "b",
        "answer_smiles": "CC(=O)O[C@]1(C)CC[C@@]23C[C@H]1C(C)(C)[C@@H]2CC[C@H]3C",
        "domain": "OATP1b1i",
        "id": 433
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O",
            "b. CC1=CC(=O)C2=C(C)C[C@H](O)[C@@H]3[C@H](OC(=O)[C@H]3C)[C@H]12",
            "c. Cc1[nH]c2ccccc2c1CN(C)C",
            "d. COC(=O)C[C@H]1C(C)(C)[C@@H](O)[C@@H]2CC3=C4C=C(OC)O[C@@H](c5ccoc5)[C@]4(C)CCC3[C@@]1(C)C2=O"
        ],
        "answer": "b",
        "answer_smiles": "CC1=CC(=O)C2=C(C)C[C@H](O)[C@@H]3[C@H](OC(=O)[C@H]3C)[C@H]12",
        "domain": "OATP1b1i",
        "id": 435
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(=O)O[C@@H]1CC[C@]2(C)[C@H](C[C@@H](OC(C)=O)[C@]3(C)C4=CC(=O)O[C@H](c5ccoc5)[C@@]4(C)CC[C@@H]23)C1(C)C",
            "b. CC(=O)[C@H]1CC[C@H]2[C@@H]3CC(=O)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",
            "c. CC(=O)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C4=CC(=O)OC4)[C@@H](OC(C)=O)C[C@]32O)C1",
            "d. C=CC1=C(C)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C=C)c(C)c4CCC(=O)O)C(CCC(=O)O)=C3C"
        ],
        "answer": "c",
        "answer_smiles": "CC(=O)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C4=CC(=O)OC4)[C@@H](OC(C)=O)C[C@]32O)C1",
        "domain": "OATP1b1i",
        "id": 436
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)C[C@H]1C2(C)CC34OC5(C)O[C@@]6([C@H](OC(C)=O)C(OC(C)=O)[C@]7(C)C(/C(=C(/O)C(C)C)C(=O)O[C@H]7c7ccoc7)[C@@]6(O5)[C@H](OC(C)=O)[C@@]3(O)C2OC(=O)C(C)C)[C@]14C",
            "b. CC(=O)O[C@@H]1C[C@@H]2C(C)(C)[C@H](O)C=C[C@@]2(C)[C@@H]2CC[C@@]3(C)C(=CC(=O)O[C@@H]3c3ccoc3)[C@@]12C",
            "c. C=CCC1(C(C)CCC)C(=O)N=C(S)NC1=O",
            "d. CC1(C)C2CC(=O)O[C@@]3(C)C4=CC(=O)O[C@@H](c5ccoc5)[C@]4(C)CCC3[C@@]2(C)C=C[C@H]1O"
        ],
        "answer": "c",
        "answer_smiles": "C=CCC1(C(C)CCC)C(=O)N=C(S)NC1=O",
        "domain": "OATP1b1i",
        "id": 437
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC1(C)[C@H](O)C[C@H](O)[C@@]2(C)[C@H]3CC[C@]4(C)[C@@H](c5ccoc5)OC(=O)[C@H]5O[C@]54[C@]3(C)[C@H](O)C[C@@H]12",
            "b. CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1",
            "c. O=c1ccc2cc(O)c(O)cc2o1",
            "d. CC(C)C1=CC2=CC[C@@H]3[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1"
        ],
        "answer": "c",
        "answer_smiles": "O=c1ccc2cc(O)c(O)cc2o1",
        "domain": "OATP1b1i",
        "id": 439
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)c1cc(O)c(=O)c2c(O)c(O)ccc2c1",
            "b. C=C[C@@](C)(O)CC[C@H]1C(=C)C[C@H](O)[C@H]2C(C)(C)CCC[C@]12C",
            "c. CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\\CCC=C(C)C)C(=O)O",
            "d. COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1"
        ],
        "answer": "d",
        "answer_smiles": "COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1",
        "domain": "OATP1b1i",
        "id": 440
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C",
            "b. C=C1[C@@H]2CC[C@@]3(C)[C@H](c4ccoc4)OC(=O)C[C@]13O[C@H]1CC(=O)C(C)(C)[C@H](CC(=O)OC)[C@]12C",
            "c. CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1",
            "d. CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1"
        ],
        "answer": "d",
        "answer_smiles": "CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1",
        "domain": "OATP1b3i",
        "id": 443
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1",
            "b. CC[C@H]1/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]2[C@H](C)[C@H](CC1)O[C@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)[C@H]2C",
            "c. CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4O)C3=O",
            "d. C=C(C)C1(O)OC(=O)C=C1OC"
        ],
        "answer": "d",
        "answer_smiles": "C=C(C)C1(O)OC(=O)C=C1OC",
        "domain": "OATP1b3i",
        "id": 445
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CNC[C@H](O)c1cccc(O)c1",
            "b. COC(=O)c1c(OC)cc2c(c1C)Oc1c(Cl)c(O)c(Cl)c(C)c1C(=O)O2",
            "c. CCC(C)C(=O)O[C@@H]1C[C@]2(C)[C@H](c3ccoc3)OC(=O)CC23OC2(C)OC34[C@H](OC(=O)C(C)C)[C@@]3(O)[C@@H](OC(=O)[C@]5(C)O[C@H]5C)[C@]5(C)C[C@@]3(O)[C@@](C)([C@H]5CC(=O)OC)C14O2",
            "d. CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O"
        ],
        "answer": "a",
        "answer_smiles": "CNC[C@H](O)c1cccc(O)c1",
        "domain": "OATP1b3i",
        "id": 447
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C",
            "b. O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O",
            "c. OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1",
            "d. COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12"
        ],
        "answer": "d",
        "answer_smiles": "COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12",
        "domain": "OATP1b3i",
        "id": 448
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1",
            "b. CC(=O)O[C@H]1CC[C@]2(C)C3=C(CC[C@H]2C1(C)C)[C@@]1(C)CC[C@H]([C@H](C)CCC=C(C)C)[C@]1(C)CC3",
            "c. COC(=O)C[C@H]1C(C)(C)C2(O)OC34CC2C(=O)[C@]1(C)C3CC[C@]1(C)C4=CC(=O)O[C@H]1c1ccoc1",
            "d. C=N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O)c1ccccc1"
        ],
        "answer": "d",
        "answer_smiles": "C=N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O)c1ccccc1",
        "domain": "OATP1b3i",
        "id": 449
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP1b3 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. C[C@@H]1C[C@H](O)[C@@]2(O)[C@]13CC(=O)OC[C@]2(C)[C@@](C)(O)C(=O)C3",
            "b. CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1",
            "c. COC(=O)C[C@H]1C2(C)CC34OC5(C)O[C@@]6([C@H](OC)C(OC(=O)C(C)C)[C@]7(C)C(/C(=C(/OC)C(C)C)C(=O)O[C@H]7c7ccoc7)[C@@]6(O5)[C@H](OC)[C@@]3(OC)C2OC(C)=O)[C@]14C",
            "d. CC(=O)Oc1cc2c(c(C)c1OC(C)=O)CC=C1[C@]2(C)CC[C@]2(C)[C@@H]3C[C@](C)(C(=O)O)CC[C@]3(C)CC[C@@]12C"
        ],
        "answer": "a",
        "answer_smiles": "C[C@@H]1C[C@H](O)[C@@]2(O)[C@]13CC(=O)OC[C@]2(C)[C@@](C)(O)C(=O)C3",
        "domain": "OATP1b3i",
        "id": 450
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP2b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1",
            "b. CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O",
            "c. CC12CCC3c4ccc(OS(=O)(=O)O)cc4CCC3C1CCC2=O",
            "d. CNCCC(Oc1ccccc1C)c1ccccc1"
        ],
        "answer": "b",
        "answer_smiles": "CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O",
        "domain": "OATP2b1i",
        "id": 453
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the OATP2b1 transporter (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CN1CCCC1c1cccnc1",
            "b. CC(C)NCC(O)COc1cccc2ccccc12",
            "c. CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(C6=CC(=O)OC6)CCC5(O)C4CCC3(O)C2)C(O)C(O)C1O",
            "d. CCCC(CCC)C(=O)O"
        ],
        "answer": "d",
        "answer_smiles": "CCCC(CCC)C(=O)O",
        "domain": "OATP2b1i",
        "id": 455
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the organic cation transporter 1 (OCT1) (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O",
            "b. CC12CCC3C4CCC(=O)C=C4CCC3C1CCC2O",
            "c. CC1(C)SC2C(NC(=O)C(N)c3ccccc3)C(=O)N2C1C(=O)O",
            "d. Oc1ncc(F)c(O)n1"
        ],
        "answer": "b",
        "answer_smiles": "CC12CCC3C4CCC(=O)C=C4CCC3C1CCC2O",
        "domain": "OCT1I",
        "id": 466
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the organic cation transporter 1 (OCT1) (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Clc1cccc(Cl)c1NC1=NCCN1",
            "b. CN1CCN2c3ccccc3Cc3ccccc3C2C1",
            "c. CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O",
            "d. Oc1ncc(F)c(O)n1"
        ],
        "answer": "a",
        "answer_smiles": "Clc1cccc(Cl)c1NC1=NCCN1",
        "domain": "OCT1I",
        "id": 469
    },
    {
        "question": "Which of the following four compounds is most likely to inhibit the organic cation transporter 1 (OCT1) (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCOc1cc(CC(=O)NC(CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O",
            "b. Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1",
            "c. O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O",
            "d. Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2"
        ],
        "answer": "a",
        "answer_smiles": "CCOc1cc(CC(=O)NC(CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O",
        "domain": "OCT1I",
        "id": 470
    },
    {
        "question": "Which of the following four chemical structures is most likely to inhibit organic cation transporter 2 (OCT2) (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. COC(=O)Nc1nc2cc(C(=O)c3cccs3)ccc2[nH]1",
            "b. CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)O",
            "c. C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O",
            "d. CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1"
        ],
        "answer": "a",
        "answer_smiles": "COC(=O)Nc1nc2cc(C(=O)c3cccs3)ccc2[nH]1",
        "domain": "OCT2I",
        "id": 471
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high aqueous solubility (≥10 μg/mL) in PBS (pH 7.4) based on their chemical structures and their public experimental data?",
        "options": [
            "a. COc1ccc(-c2cc(CS(=O)(=O)c3ccccc3)on2)cc1",
            "b. CCc1nc2oc3ccccc3c(=O)c2cc1C(=O)OC",
            "c. CC1CN(C(=O)Nc2ccc(F)cc2F)CC(C)O1",
            "d. COc1ccc(C(C)=NNc2cccc(C(=O)O)c2)cc1OC"
        ],
        "answer": "c",
        "answer_smiles": "CC1CN(C(=O)Nc2ccc(F)cc2F)CC(C)O1",
        "domain": "PBS74",
        "id": 481
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high aqueous solubility (≥10 μg/mL) in PBS (pH 7.4) based on their chemical structures and their public experimental data?",
        "options": [
            "a. Cc1nc(-c2ccc([N+](=O)[O-])cc2)nc2[nH]ccc(=O)c12",
            "b. S=C(Nc1ccccc1)Nc1ccccc1-n1cccc1",
            "c. O=C(Nc1ccno1)Nc1ccc(Cl)cc1Cl",
            "d. CCCOc1ccccc1C=C1SC(N)=NC1=O"
        ],
        "answer": "b",
        "answer_smiles": "S=C(Nc1ccccc1)Nc1ccccc1-n1cccc1",
        "domain": "PBS74",
        "id": 489
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high aqueous solubility (≥10 μg/mL) in PBS (pH 7.4) based on their chemical structures and their public experimental data?",
        "options": [
            "a. Cc1nc2ccccc2c(=O)n1N=Cc1ccc(C(C)(C)C)cc1",
            "b. O=c1[nH]nc(-c2ccc(F)cc2)cc1Cc1ccccc1",
            "c. Cc1cccc(NC(=O)c2ccc(S(=O)(=O)N3CCCC3)cc2)c1C",
            "d. CC(C)(C)C(=O)C(C#N)=Cc1cccs1"
        ],
        "answer": "d",
        "answer_smiles": "CC(C)(C)C(=O)C(C#N)=Cc1cccs1",
        "domain": "PBS74",
        "id": 490
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high human plasma protein binding (PPB) (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. Nc1cccc(-c2ccc(Cn3cc(C(=O)O)c(=O)c4cccc(F)c43)cn2)c1",
            "b. Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Br)n[nH]1",
            "c. CCC(C(=O)NC(C=CC(=O)OC1CCC1)CC1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O",
            "d. CC(C(=O)OC1C[N+]2(Cc3nc(-c4ccccc4)no3)CCC1CC2)(c1ccccc1)N1CCCCC1"
        ],
        "answer": "b",
        "answer_smiles": "Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Br)n[nH]1",
        "domain": "PPBhuman",
        "id": 502
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high human plasma protein binding (PPB) (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CC(C)(NS(=O)(=O)c1ccc2c(Cl)cnc(N=C(N)N)c2c1)C(=O)O",
            "b. CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1",
            "c. Nc1noc2ccc(-n3nc(C(F)(F)F)c4c3C(=O)N(c3ccc(-c5ccccc5CN5CCCC5)cc3F)CC4)cc12",
            "d. O=C(NCC1(CO)CCCC1)c1nc(N2CCOCC2)n2ccccc12"
        ],
        "answer": "a",
        "answer_smiles": "CC(C)(NS(=O)(=O)c1ccc2c(Cl)cnc(N=C(N)N)c2c1)C(=O)O",
        "domain": "PPBhuman",
        "id": 503
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high human plasma protein binding (PPB) (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CN(C)Cc1cccc(-c2ccc(Cn3cc(C(=O)O)c(=O)c4cccc(F)c43)cc2)c1",
            "b. Nc1ccn(C2CSC(CO)O2)c(=O)n1",
            "c. C[C@@](C(=O)O[C@H]1C[N+]2(CCCc3ccncc3)CCC1CC2)(c1ccccc1)N1CCCCC1",
            "d. CC#CCn1c(N2CCCC(N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C"
        ],
        "answer": "b",
        "answer_smiles": "Nc1ccn(C2CSC(CO)O2)c(=O)n1",
        "domain": "PPBhuman",
        "id": 504
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high human plasma protein binding (PPB) (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. O=C1CC(c2cc(F)c(F)c(F)c2)CN1Cc1ccncc1F",
            "b. COC(=O)c1cccc(-n2sc3ccccc3c2=O)c1",
            "c. COc1ccc(S(=O)(=O)N(CC(C)C)CC(O)C(Cc2ccc(NCCCc3ccccc3-c3sc4c(c3C(=O)O)CC(C)(C)CC4)cc2)NC(=O)OC2COC3(C)OCCC23)cc1",
            "d. Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F"
        ],
        "answer": "d",
        "answer_smiles": "Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F",
        "domain": "PPBhuman",
        "id": 507
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit high human plasma protein binding (PPB) (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2n1-c1cccnc1",
            "b. O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12",
            "c. N=C(N)NCCCC(NC(=O)CN1CCN(S(=O)(=O)c2ccc3c(Cl)cccc3c2)CC1=O)C(=O)c1nccs1",
            "d. O=C(O)c1ccc(Oc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)CC4c4cccc(Cl)c4)CC3)cn2)cc1"
        ],
        "answer": "b",
        "answer_smiles": "O=c1cc(N2CCOCC2)nc2n(Cc3cccc(Cl)c3Cl)ccn12",
        "domain": "PPBhuman",
        "id": 508
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. Cc1ccn2c(C(=O)NCc3ccc(Oc4ccc(Cl)cc4)cc3)c(C)nc2c1",
            "b. O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1",
            "c. Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C",
            "d. CC(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12"
        ],
        "answer": "d",
        "answer_smiles": "CC(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12",
        "domain": "PPBmouse",
        "id": 511
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CS(=O)(=O)N(CCO)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12",
            "b. N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1",
            "c. CC1OCCC2Oc3ccc(-c4cccnc4F)cc3C3(N=C(N)N(C)C3=O)C12",
            "d. O=c1[nH]c2ccc(-c3c(Cl)cccc3OC(F)(F)F)cc2[nH]1"
        ],
        "answer": "b",
        "answer_smiles": "N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1",
        "domain": "PPBmouse",
        "id": 512
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CC(CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12",
            "b. FCCCOc1ccc2nc(Nc3ccncc3)ccc2c1",
            "c. CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1",
            "d. CC1(C)Cc2c(CN3CCC4(CC3)CCN(C(=O)c3ccnc(N)c3)CC4)cccc2O1"
        ],
        "answer": "a",
        "answer_smiles": "CC(CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12",
        "domain": "PPBmouse",
        "id": 513
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC",
            "b. CCS(=O)(=O)Nc1cnc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(F)cc(F)c1O2",
            "c. Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O",
            "d. COC(=O)NC(C(=O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C"
        ],
        "answer": "c",
        "answer_smiles": "Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O",
        "domain": "PPBmouse",
        "id": 514
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CC(CC(=O)O)c1cccc(-n2c(C(N)=O)cc3ccc(OC(F)(F)F)cc32)n1",
            "b. Cc1cc(C2CCN(C(=O)C3CN(C(C)(C)C)CC3c3ccc(F)cc3F)CC2)n(-c2ccc(F)c(Cl)c2)n1",
            "c. c1cn(-c2cc(NC3=NCC4(CN5CCC4CC5)O3)ncn2)cn1",
            "d. CC1(N)CC(C(=O)N2CCC(c3ccnn3-c3ccc(F)c(Cl)c3)CC2)C(c2ccc(F)cc2F)C1"
        ],
        "answer": "c",
        "answer_smiles": "c1cn(-c2cc(NC3=NCC4(CN5CCC4CC5)O3)ncn2)cn1",
        "domain": "PPBmouse",
        "id": 516
    },
    {
        "question": "Which of the following four compounds is most likely to show strong binding to mouse plasma proteins (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. COc1cc(Nc2nccc(Nc3cnc4ccccc4c3)n2)cc(OC)c1OC",
            "b. Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2",
            "c. Cc1cccc(C=NNc2cc(N3CCOCC3)n3nc(-c4ccncc4)cc3n2)c1",
            "d. O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CC1"
        ],
        "answer": "c",
        "answer_smiles": "Cc1cccc(C=NNc2cc(N3CCOCC3)n3nc(-c4ccncc4)cc3n2)c1",
        "domain": "PPBmouse",
        "id": 517
    },
    {
        "question": "Which of the following four compounds is most likely to show high rat plasma protein binding (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1",
            "b. OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1",
            "c. CC(Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc4nccs4)c3)c12)C(=O)N1CCOCC1",
            "d. CC1NC(=O)c2cc(-c3cccc4c(=O)n(C)c(NC(C)(C)C)nc34)[nH]c21"
        ],
        "answer": "b",
        "answer_smiles": "OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1",
        "domain": "PPBrat",
        "id": 521
    },
    {
        "question": "Which of the following four compounds is most likely to show high rat plasma protein binding (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3C)n1",
            "b. COc1ccc(S(=O)(=O)N(CC(C)C)CC(O)C(Cc2ccc(N3CC(Oc4ccccc4-c4sc5c(c4C(=O)O)CC(C)(C)CC5)C3)cc2)NC(=O)OC2COC3(C)OCCC23)cc1",
            "c. O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccn4)c3)c2s1",
            "d. CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3)c(F)c2)cc1"
        ],
        "answer": "c",
        "answer_smiles": "O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccn4)c3)c2s1",
        "domain": "PPBrat",
        "id": 526
    },
    {
        "question": "Which of the following four compounds is most likely to show high rat plasma protein binding (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1",
            "b. CCCCCCCC1(CC)C(=O)NC(=O)NC1=O",
            "c. Cc1nc2c(s1)CCC2C(=O)Nc1ccc(CC2CCC(C(O)c3cccnc3)N2)cc1",
            "d. CCCC1(C(=O)c2ccc(N)c(Cl)c2)CCCN1"
        ],
        "answer": "a",
        "answer_smiles": "C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1",
        "domain": "PPBrat",
        "id": 527
    },
    {
        "question": "Which of the following four compounds is most likely to show high rat plasma protein binding (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",
            "b. CC1(C)CN(Cc2ccc3c(c2)c(=O)c(C(N)=O)cn3-c2ccc(F)cc2)CCO1",
            "c. CCCN(CCCNc1nc(N)n2nc(-c3ccco3)nc2n1)CCc1cccc2c1CC(=O)N2",
            "d. CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21"
        ],
        "answer": "d",
        "answer_smiles": "CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21",
        "domain": "PPBrat",
        "id": 528
    },
    {
        "question": "Which of the following four compounds is most likely to show high rat plasma protein binding (%fb>=70%) based on the public experimental data?",
        "options": [
            "a. CN1CCOCC1C(=O)N1CCC(O)(c2ccccc2)C2CCCCC21",
            "b. CCCOCCn1c(=O)c(N2CCNCC2)nc2cnc(-c3ccc(OC)nc3)cc21",
            "c. Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CC(F)CC2COc2ccc(C(=O)O)cc2)cc1Cl",
            "d. COc1cc(F)cc2c1nnc1c2c(-c2ccncc2C)nn1C"
        ],
        "answer": "b",
        "answer_smiles": "CCCOCCn1c(=O)c(N2CCNCC2)nc2cnc(-c3ccc(OC)nc3)cc21",
        "domain": "PPBrat",
        "id": 529
    },
    {
        "question": "Which of the following four compounds is most likely to act as an inhibitor of P-glycoprotein (P-gp) (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCC(C(=O)OCCCN1CCN(CCCOC(=O)C(CC)c2ccccc2)CC1)c1ccccc1",
            "b. COCCc1ccc(OCC(O)CNC(C)C)cc1",
            "c. COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1OCC(=O)N1CCN(Cc2ccc(OC)c(OC)c2OC)CC1",
            "d. C=C1C(OC(=O)c2ccccc2)C(OC(C)=O)C(OC(C)=O)C(C)(C)C=CC(C)C(=O)C2(O)CC(C)C(O)C2C1OC(=O)C(C)CC"
        ],
        "answer": "d",
        "answer_smiles": "C=C1C(OC(=O)c2ccccc2)C(OC(C)=O)C(OC(C)=O)C(C)(C)C=CC(C)C(=O)C2(O)CC(C)C(O)C2C1OC(=O)C(C)CC",
        "domain": "PgpI",
        "id": 538
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for P-glycoprotein (P-gp) (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(=O)O",
            "b. CCOP(=S)(OCC)SC(CCl)N1C(=O)c2ccccc2C1=O",
            "c. CCCCNP1(NCCCC)=NP(NCCCC)(NCCCC)=NP(NCCCC)(NCCCC)=NP(NCCCC)(NCCCC)=N1",
            "d. CC(C)N1CCC(N(C(=O)Cc2ccccc2)c2ccc(Cl)cc2)CC1"
        ],
        "answer": "c",
        "answer_smiles": "CCCCNP1(NCCCC)=NP(NCCCC)(NCCCC)=NP(NCCCC)(NCCCC)=NP(NCCCC)(NCCCC)=N1",
        "domain": "PgpS",
        "id": 545
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for P-glycoprotein (P-gp) (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. C=CCc1[nH]c2c(OCc3ccccc3)cc(N(CC=C)C(C)=O)cc2c1C",
            "b. COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC",
            "c. CCCCCCCCCCCCP(=O)(O)OCC(N)C(=O)O",
            "d. O=C1C(Cl)=C(Nc2ccc3c[nH]nc3c2)C(=O)c2ccccc21"
        ],
        "answer": "b",
        "answer_smiles": "COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC",
        "domain": "PgpS",
        "id": 549
    },
    {
        "question": "Which of the following four compounds is most likely to act as a substrate for P-glycoprotein (P-gp) (EC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C1C(Cl)=C(N2CCN(C3=C(Cl)C(=O)c4ccccc4C3=O)CC2)C(=O)c2ccccc21",
            "b. CN(C)CCN1C(=O)Nc2c3cc(O)ccc3nc3c([N+](=O)[O-])ccc1c23",
            "c. CCCC(=O)Nc1cc(C=CC(=O)N2CC(CCl)c3c2cc(OCc2ccccc2)c2[nH]cc(C)c32)n(C)c1",
            "d. Cc1ccc(N=C2C=C(O)C(=O)c3ccccc32)c(C)c1"
        ],
        "answer": "b",
        "answer_smiles": "CN(C)CCN1C(=O)Nc2c3cc(O)ccc3nc3c([N+](=O)[O-])ccc1c23",
        "domain": "PgpS",
        "id": 550
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)c(Cl)c1)C2",
            "b. Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C(F)(F)F)C3)ccn1",
            "c. Nc1ccnc(Nc2ccc(Oc3ccncc3)cc2)n1",
            "d. O=c1[nH]cc(-c2ccccc2)cc1-c1ccccc1"
        ],
        "answer": "b",
        "answer_smiles": "Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C(F)(F)F)C3)ccn1",
        "domain": "RMS",
        "id": 554
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. N#Cc1cc(N)ncc1-c1cc(N2CCOCC2)nc(N2CCOCC2)n1",
            "b. N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1",
            "c. C=C1CC1NC1CCN(c2ccc(NC(=O)C(C)(C)c3ccccc3)cc2Cl)CC1",
            "d. CC(C)c1nc(-c2ccc(F)c(NS(=O)(=O)c3c(F)cccc3F)c2)c(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)s1"
        ],
        "answer": "b",
        "answer_smiles": "N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1",
        "domain": "RMS",
        "id": 555
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. Cc1nn(CCN(C)C)c(C)c1CC(=O)NCc1ccc(F)cc1Cl",
            "b. CCC(C)CN1C(=O)c2ccccc2C(C(=O)O)C1c1cc2ccccc2o1",
            "c. NC1CCCN(c2c(Br)cccc2C=C2SC(=O)NC2=O)C1",
            "d. COc1n[nH]c2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(C)(C)C#N)c4)ccc3F)cc12"
        ],
        "answer": "d",
        "answer_smiles": "COc1n[nH]c2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(C)(C)C#N)c4)ccc3F)cc12",
        "domain": "RMS",
        "id": 559
    },
    {
        "question": "Which of the following four compounds is most likely to be cleared in a rat microsome assay, with measured clearance ≥30% of hepatic blood flow, based on public experimental data?",
        "options": [
            "a. CC(C)CN1CC2C(CNc3nc(-c4ccccn4)cs3)C2C1",
            "b. O=C(O)c1ccc(OC2CCN(C(=O)NC3CC3c3ccccc3)CC2)c(Cl)c1",
            "c. CN1C(=O)Cc2cc(-c3cc(C(O)(C(F)(F)F)C(F)(F)F)cnc3N3CCN(S(=O)(=O)c4ccc(N)nc4)CC3)ccc21",
            "d. c1cc2c(cc1OCC1CCNCC1)CCN(C1CCC1)CC2"
        ],
        "answer": "c",
        "answer_smiles": "CN1C(=O)Cc2cc(-c3cc(C(O)(C(F)(F)F)C(F)(F)F)cnc3N3CCN(S(=O)(=O)c4ccc(N)nc4)CC3)ccc21",
        "domain": "RMS",
        "id": 560
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the antioxidant response element (ARE) (<=10uM) in a stress response assay based on the public experimental data?",
        "options": [
            "a. O=C(O)CN(CC(=O)O)CC(=O)O",
            "b. CC(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1",
            "c. O=Cc1ccc(F)cc1",
            "d. Clc1sc(Cl)c(Cl)c1Cl"
        ],
        "answer": "a",
        "answer_smiles": "O=C(O)CN(CC(=O)O)CC(=O)O",
        "domain": "SR-ARE",
        "id": 561
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the antioxidant response element (ARE) (<=10uM) in a stress response assay based on the public experimental data?",
        "options": [
            "a. COc1ccccc1OC(=O)Oc1ccccc1OC",
            "b. NC(=O)c1cccc([N+](=O)[O-])c1",
            "c. N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O",
            "d. CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O"
        ],
        "answer": "d",
        "answer_smiles": "CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O",
        "domain": "SR-ARE",
        "id": 564
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the antioxidant response element (ARE) (<=10uM) in a stress response assay based on the public experimental data?",
        "options": [
            "a. CCOC(=O)C(Cl)C(C)=O",
            "b. CC(=O)Nc1ncc([N+](=O)[O-])s1",
            "c. CC(C)CCCCCCOC(=O)C1CCCCC1C(=O)OCCCCCCC(C)C",
            "d. CCCOC/C(=N\\c1ccc(Cl)cc1C(F)(F)F)n1ccnc1"
        ],
        "answer": "d",
        "answer_smiles": "CCCOC/C(=N\\c1ccc(Cl)cc1C(F)(F)F)n1ccnc1",
        "domain": "SR-ARE",
        "id": 567
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the ATAD5-mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. CCOc1cc(Oc2ccc(C(F)(F)F)cc2Cl)ccc1[N+](=O)[O-]",
            "b. Cc1ncc([N+](=O)[O-])n1CCO",
            "c. CCC(C)(c1ccc(O)cc1)c1ccc(O)cc1",
            "d. Nc1ccc(Oc2ccc(N)c(N)c2)cc1"
        ],
        "answer": "d",
        "answer_smiles": "Nc1ccc(Oc2ccc(N)c(N)c2)cc1",
        "domain": "SR-ATAD5",
        "id": 577
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the heat shock element (HSE) stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. C=CC(=O)NC(C)C",
            "b. O=c1[nH]c2cc(C(F)(F)F)c(N3CCOCC3)cc2n(CP(=O)(O)O)c1=O",
            "c. O=C(O)C1C2CCC(O2)C1C(=O)O",
            "d. CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O"
        ],
        "answer": "d",
        "answer_smiles": "CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O",
        "domain": "SR-HSE",
        "id": 581
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the heat shock element (HSE) stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. CC1(C)C2CCC3(C2)[C@H]1C(=O)CCC3(C)C",
            "b. CCCCCCCO",
            "c. O=C(O)CC(O)(CC(=O)O)C(=O)O",
            "d. C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O"
        ],
        "answer": "c",
        "answer_smiles": "O=C(O)CC(O)(CC(=O)O)C(=O)O",
        "domain": "SR-HSE",
        "id": 587
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the Matrix Metalloproteinase (MMP) mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. CC(C)CC(C)(O)C#CC(C)(O)CC(C)C",
            "b. O=C(C=Cc1ccccc1)OCC=Cc1ccccc1",
            "c. Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br",
            "d. O=C(O)C1O[Sb]2OC(=O)C(O2)C(C(=O)O)O[Sb]2OC(=O)C1O2"
        ],
        "answer": "a",
        "answer_smiles": "CC(C)CC(C)(O)C#CC(C)(O)CC(C)C",
        "domain": "SR-MMP",
        "id": 592
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the Matrix Metalloproteinase (MMP) mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. O=c1nn[nH]c2ccccc12",
            "b. Cc1cc(O)c(Cl)c(C)c1Cl",
            "c. O=C1c2ccccc2CN2C(=O)c3ccccc3CN12",
            "d. CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O"
        ],
        "answer": "b",
        "answer_smiles": "Cc1cc(O)c(Cl)c(C)c1Cl",
        "domain": "SR-MMP",
        "id": 593
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the Matrix Metalloproteinase (MMP) mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. CCCCOC(=O)C(C)Oc1ccc(Oc2ccc(C(F)(F)F)cn2)cc1",
            "b. c1ccc(CNc2ncnc3c2ncn3C2CCCCO2)cc1",
            "c. COC(C)(C)CCCC(C)C/C=C/C(C)=C/C(=O)OC(C)C",
            "d. C=CC(=O)O"
        ],
        "answer": "c",
        "answer_smiles": "COC(C)(C)CCCC(C)C/C=C/C(C)=C/C(=O)OC(C)C",
        "domain": "SR-MMP",
        "id": 594
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the Matrix Metalloproteinase (MMP) mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. O=P(O)(O)OC[C@H](O)CO",
            "b. NCCS(=O)(=O)O",
            "c. COC(=O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1",
            "d. CCCCCCCCCCCCCCCCCCOS(=O)(=O)O"
        ],
        "answer": "b",
        "answer_smiles": "NCCS(=O)(=O)O",
        "domain": "SR-MMP",
        "id": 596
    },
    {
        "question": "Which of the following four compounds is most likely to interact with the p53-mediated stress response pathway (<=10uM) based on the public experimental data?",
        "options": [
            "a. CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O",
            "b. CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1",
            "c. CC1CC(=O)CC(C)(C)C1",
            "d. CCc1cccc(CC)c1NC(=O)CN(CC(=O)O)CC(=O)O"
        ],
        "answer": "a",
        "answer_smiles": "CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O",
        "domain": "SR-p53",
        "id": 605
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit hERG inhibition (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Cc1nn(C2CCNCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1",
            "b. Cc1ccc(S(N)(=O)=O)c(C)c1C(=O)N1CCC(CCN2C3CCC2CC(n2c(C)nc4ccccc42)C3)(c2cccc(F)c2)CC1",
            "c. CCC1(c2ccccc2)C(=O)N=C(O)NC1=O",
            "d. Cc1cc(C#Cc2cn(-c3ccc(F)cc3)c(C)n2)ccn1"
        ],
        "answer": "c",
        "answer_smiles": "CCC1(c2ccccc2)C(=O)N=C(O)NC1=O",
        "domain": "hERG",
        "id": 615
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit hERG inhibition (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. O=C(CCCCCCC(=O)Nc1ccccc1)NO",
            "b. CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl",
            "c. O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@@H](CO)c1ccccc1",
            "d. CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3ccccc31)C2)c1ccccc1"
        ],
        "answer": "d",
        "answer_smiles": "CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3ccccc31)C2)c1ccccc1",
        "domain": "hERG",
        "id": 616
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit hERG inhibition (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. Nc1ccc(-c2cnc3nc(N4CCC(N5CCCCC5)CC4)sc3c2)cn1",
            "b. COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1",
            "c. CCC[C@@H](CCO)Nc1nc(N)nc(C)c1Cc1ccc(CN2CCCC2)cc1OC",
            "d. NS(=O)(=O)c1ccc(CCNc2nc(Cl)nc3cccc(-c4ccccc4)c23)cc1"
        ],
        "answer": "b",
        "answer_smiles": "COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1",
        "domain": "hERG",
        "id": 617
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit hERG inhibition (IC50<=10uM) based on the public experimental data?",
        "options": [
            "a. CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cc(O)ccc32)cc1",
            "b. N#Cc1ccc(OCCCN2CC3CN(CC(=O)NCCc4ccccc4)CC(C2)O3)cc1",
            "c. O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1",
            "d. Cc1nc(Oc2ccc(C(=O)N3CCOCC3)cc2)ccc1CN1CCC(N(C(=O)Nc2ccc(C(N)=O)nc2)c2cccc(F)c2)CC1"
        ],
        "answer": "c",
        "answer_smiles": "O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1",
        "domain": "hERG",
        "id": 619
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit nephrotoxicity based on the public experimental data?",
        "options": [
            "a. O=C(O)CNC(=O)CNC(=O)CNC(=O)CSC(=O)c1ccccc1",
            "b. COc1ccc(-c2cc(=O)c3c(O)cc(O)c(-c4cc(-c5cc(=O)c6c(O)cc(OC)cc6o5)ccc4OC)c3o2)cc1",
            "c. NCC1CCC(C(=O)O)CC1",
            "d. O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]"
        ],
        "answer": "b",
        "answer_smiles": "COc1ccc(-c2cc(=O)c3c(O)cc(O)c(-c4cc(-c5cc(=O)c6c(O)cc(OC)cc6o5)ccc4OC)c3o2)cc1",
        "domain": "nephrotox",
        "id": 623
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit nephrotoxicity based on the public experimental data?",
        "options": [
            "a. O=C(O)CN1CCN(CC(=O)O)CCN(C(CO)C(O)CO)CCN(CC(=O)O)CC1",
            "b. COP(C)(=O)OC",
            "c. C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1",
            "d. N=C(N)c1ccc2cc(OC(=O)c3ccc(N=C(N)N)cc3)ccc2c1"
        ],
        "answer": "b",
        "answer_smiles": "COP(C)(=O)OC",
        "domain": "nephrotox",
        "id": 625
    },
    {
        "question": "Which of the following four compounds is most likely to exhibit nephrotoxicity based on the public experimental data?",
        "options": [
            "a. Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",
            "b. CCC(CCC(C)C1CCC2C3CC=C4CC(OC5OC(CO)C(O)C(O)C5O)CCC4(C)C3CCC12C)C(C)C",
            "c. COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21",
            "d. NC(N)=NC(=O)c1nc(Cl)c(N)nc1N"
        ],
        "answer": "c",
        "answer_smiles": "COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21",
        "domain": "nephrotox",
        "id": 627
    }
]